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Optimization of the mediation of acute thrombi remains a significant research 
challenge in the treatment of emergency conditions including heart attack and ischemic 
stroke. We have demonstrated that a nanoparticle carrying potent direct thrombin 
inhibitors can advance the treatment of acute thrombosis arising from various  
cardiovascular pathologies. The thrombin-inhibiting nanoparticles presented herein are 
designed to focus the antithrombotic impact of direct thrombin inhibitors at the site of 
thrombus formation and to provide imaging contrast to highlight the formation or the 
abatement and eventual disintegration of the thrombus.  
Perfluorocarbon nanoparticles were functionalized by covalent addition of PPACK 
or bivalirudin to carboxy-PEG capped lipid components to the stabilizing lipids. Over 
10000 inhibitors were added per particle. In vitro experiments evaluated inhibition of 
thrombin cleavage of the chromogenic substrate Chromozym TH and defined the 
kinetics of the particle-thrombin interaction. Thrombin-inhibiting activity of the 
component inhibitors was undiminished on the nanoparticles and, as explored in 
viii 
appended work, the nanoparticles had a significant kinetic advantage over the lone 
inhibitors. 
To demonstrate efficacy of the particles as inhibitors of clot-bound thrombin, 
fibrinopeptide A ELISAs assayed the production of fibrin in plasma exposed to the 
surface of forming clots treated with PPACK, bivalirudin, PPACK nanoparticles, or 
bivalirudin nanoparticles. Similarly treated clots were monitored for growth in plasma 
via magnetic resonance imaging. Nanoparticles exceeded the activity of the component 
inhibitors in blocking FPA production by bound thrombin and formed an inhibitory layer 
that stopped further growth of clots in plasma. 
 In vivo testing of thrombosis inhibition was performed in C57BL/6 mice and NZW 
rabbits using the Rose Bengal laser-induced thrombosis model (with ultrasonic flow 
probes tracking progress to occlusive thrombus). Thrombin-inhibiting particles were 
compared to Heparin, PPACK, bivalirudin, saline, and analogous non-functionalized 
particles as inhibitors of acute thrombosis in mice. Thrombin-inhibiting nanoparticles 
significantly delayed occlusion time in mice, outperforming heparin and the component 
inhibitors. Ultrasound and magnetic resonance imaging were employed to evaluate 
deposition of nanoparticles in mouse or rabbit thrombi. Thrombi were analyzed 
following in vivo experiments, using imaging and histochemical methods. Magnetic 
resonance imaging and spectroscopy revealed the specific deposition of thrombin-
inhibiting nanoparticles in thrombi. For evaluation of fine clot morphology, mouse 
thrombi were examined with transmission electron microscopy. For evaluation of fibrin 
ix 
and platelet content in the thrombus Carstair’s staining was employed. Clots formed 
following nanoparticle administration exhibited lesser platelet content. 
In additional experiments, bleeding times and APTT measurements determined the 
systemic effects of the nanoparticles. Though the thrombin-inhibiting nanoparticles 
delayed thrombotic occlusion at a site of arterial injury to 1.5-2 hours, significant effects 
on blood pool coagulation parameters were observed for less than 20 minutes. 
We have demonstrated that the thrombin-inhibiting nanoparticle is kinetically 
superior to conventional direct inhibitors. In vivo, the potent inhibition kinetics, 
combined with the pharmacokinetic and pharmacodynamic properties of 
perfluorocarbon nanoparticles enabled superior inhibition of thrombosis while 
maintaining an excellent safety profile with short-lived systemic effects. Imaging data 
indicated the formation of layers of nanoparticles at sites of arterial injury. Thrombin-
inhibiting nanoparticles are thus derived here as a new tool for treatment of acute 
thrombosis. The particles open a new avenue in this field of medical research as the 
first therapeutic to form a detectable, site-specific, and quantifiable anticoagulant layer 
that seals against the progress of acute thrombosis.   
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Chapter 1  
Specific Aims, Background, and Significance 
1.1   Specific Aims 
Millions die or are disabled each year from acute strokes or heart attacks that are 
caused by the highly localized formation of blood clots resulting in occlusion of the carotid 
or coronary arteries.  In cases where premonitory symptoms or signs of disease indicate 
the risk of an acute event, a cocktail of various anticoagulants and antiplatelet agents is 
administered both orally and intravenously to prevent clot progression1-5. Even with 
aggressive treatment regimens, thrombus formation still proceeds unpredictably6,7. 
Conversely, severe or fatal bleeding problems can arise with the systemically active 
anticoagulants in use today8. Accordingly, the development of safer and more effective 
anticoagulants remains both a challenge and an active pursuit for management of the 
unstable clot-prone atherosclerotic plaques that are the major source of heart attack and 
stroke1,3,5,9-13.  
The overarching aim of this work is the development antithrombotic soft nanoparticles. 
These particles represent first-in-class anticoagulants with intrinsic magnetic resonance 
contrast, concentrated therapeutic impact defined by thrombin-targeted particle surfaces, 
and pharmacokinetics optimized by the base particles. Although nanoparticles have been 
used as delivery agents for common anticoagulants14, none have been conceptualized or 
demonstrated in vivo as integrated antithrombotics where the nanoparticle itself plays a 
critical role in preventing coagulation by forming active thrombin-inhibiting surfaces at sites 
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of vascular injury. As potent new antithrombotics that can be traced with medical imaging 
techniques, these nanoparticles are promising therapeutics. 
 
SPECIFIC AIM #1: Design, synthesize, and chemically characterize PPACK thrombin-
inhibitor nanoparticles. The irreversible thrombin inhibitor, PPACK (Phe(D)-Pro-Arg-
Chloromethylketone), will be covalently attached to perfluorocarbon (PFC) emulsion 
nanoparticles. HPLC, zeta potential, and particle sizing will characterize the particles. 
Optical assay will verify PPACK NP activity against thrombin and enable modeling of the 
kinetics of the thrombin-nanoparticle interaction. 
SPECIFIC AIM #2: Demonstrate efficacy of PPACK antithrombotic nanoparticles in vivo 
following acute arterial injury. PPACK nanoparticles will be compared to heparin, PPACK, 
non-functionalized NPs, and saline in a mouse arterial thrombosis model. Performance will 
be assessed through Doppler blood flow measurement and transmission electron 
microscopy and immunohistochemistry assessment of clot morphology. Side effects will be 
monitored via measurement of coagulation parameters (bleeding time, prothrombin time 
and activated partial thromboplastin time) in the blood pool. 
SPECIFIC AIM #3: Design, synthesize, and characterize particles carrying Bivalirudin. 
Employing the methods of aim #1, Bivalirudin will be conjugated to particles. Activity of the 
bivalirudin nanoparticle and bivalirudin against thrombin will be characterized as in aim #1. 
Distinct kinetic models will be applied to the new agent, accounting for the bivalent and 
reversible bivalirudin-thrombin interaction. Bivalirudin nanoparticle (and PPACK 
nanoparticle) activity against bound thrombin will be evaluated through fibrinopeptide A 
ELISA and observation of coagulation progress. 
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SPECIFIC AIM #4: Demonstrate efficacy of Bivalirudin antithrombotic nanoparticles in vivo 
following acute arterial injury. In addition to the tested groups of aim #2, bivalirudin and 
bivalirudin nanoparticles will be tested for activity in prevention of acute thrombosis. Clots 
will be characterized as in aim #2. The bivalirudin nanoparticle therapy is designed to 
produce superior inhibition of thrombosis due to bivalirudin’s activity against fibrin-bound 
thrombin and ideal specificity for thrombin. Assessment of side effects will be determined 
via measurement of blood pool coagulation parameters as in aim #2. 
SPECIFIC AIM #5: Demonstrate that antithrombotic nanoparticles provide imaging 
contrast to specifically locate sites of thrombosis. 19F MR will assess PFC nanoparticle 
retention in clots. Both the PPACK and bivalirudin particles will be compared to non-
functionalized particles for retention in thrombi as evaluated by quantitative 19F MR 
spectroscopy ex vivo. Analogously obtained in vitro data will evaluate PPACK and 
bivalirudin binding to and dissociation from human fibrin clots. Towards demonstration of 
translation to clinical imaging, in vivo tracking of thrombosis and specific retention of the 
particles at the site of thrombosis will be demonstrated using clinical field strength MR 
angiography and diffusion-weighted 1H imaging in an arterial injury model in rabbits. 
 
1.2   Background  
THROMBIN 
Thrombin is a well-characterized trypsin-like serine protease implicated in various 
processes in coagulation. Its principal action entails gating the penultimate step in the 
coagulation cascade by cleaving fibrinogen to produce insoluble and polymerizable fibrin, 
which in turn stabilizes a forming platelet aggregate4,15,16. In coagulation, thrombin also 
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contributes to the activation of platelets via cleavage of G protein-coupled protease-
activated receptors (PARs)4,15,17-21. The central role of thrombin as a rate-limiting factor in 
clotting renders it an ideal target for development of novel anticoagulants2,4. 
Moreover, thrombin’s activation of PARS provides it with potentially multifaceted roles 
in various vascular disorders. Specifically, thrombin induces inflammatory phenotypes in 
endothelial cells, resulting in more permeable vascular lesions17,19-23. It has also been 
implicated in vascular smooth muscle cell pathways promoting atherosclerosis via its 
action against PAR-1.  In smooth muscle cells, PARs mediate contraction, migration, 
proliferation, hypertrophy, and extracellular matrix production. In this sense, thrombin plays 
a role in the pathophysiology of vascular diseases such as atherosclerosis17.19-21,23. More 
basically, its retention in developing and deteriorating plaques has potential implications in 
the long-term mediation and treatment of atherosclerosis23-25. Due to these mechanisms, 
in addition to fibrin production in acute thrombus, thrombin represents a potential target for 
treatment in a variety of cardiovascular pathologies.  
THROMBIN INHIBITION 
Anticoagulants that are mechanistically based on thrombin inhibition abound in 
standard clinical practice. Coumarin derivatives and heparins are mainstays in prevention 
and treatment of thrombosis. Nonetheless, coumarins act against thrombin by hindering 
steps in the post-translational modification of prothrombin and similar proteins (including 
protein C, which acts against the formation of active thrombin) and accordingly must be 
considered as slow-acting and non-specific inhibitors of thrombosis26,27. The well-known 
difficulties with coumarin entail very narrow margins between therapeutic benefit and 
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toxicity, requiring frequent and expensive monitoring, dietary discretion, and awareness of 
bleeding complications8. 
Heparins are more specific in their activity against thrombin, but still impose an indirect 
form of inhibition, by interacting with naturally occurring thrombin inhibitors. Most notably, 
heparin binding dramatically accelerates the inhibition of thrombin by antithrombin and by 
heparin cofactor II28. Heparins are accordingly restricted by sufficient production of the 
inhibitors for which it acts as a cofactor.  Deficiencies in antithrombin or heparin cofactor II 
are well documented7,29-31. Further evidence indicates that the activity of antithrombin-
heparin is significantly abated when the inhibitory complex is bound in a growing 
thrombus32. It may be preferable to address thrombin inhibition with direct, high-affinity, 
and specific inhibitors. 
The design of specific and potent direct thrombin inhibitors has garnered attention from 
numerous researchers. A large variety of inhibitors have been derived from either naturally 
occurring or de novo designed inhibitors. However, problems of specificity, toxicity, and 
unacceptable circulating half-life have plagued many otherwise promising lead 
compounds3,33.  
Aside from the highly notable exception of the leech antithrombin polypeptide hirudin 
and its derivatives, discovery of direct thrombin inhibitors has largely focused on 
exploration of the thrombin-sensitive region of fibrinogen. The Gly-Pro-Arg-H and Phe-Val-
Arg-H tripeptides garnered significant early interest, showing ability to bind in thrombin’s 
active site pocket via recognition of the C-terminal arginine side chain and reaction with 
the catalytic residues2,34,35. Systematic study of the N-terminal residue of the Gly-Pro-Arg-
6 
H tripeptide yielded discovery of D-Phe-Pro-Arg-H as an optimally strong and highly 
specific inhibitor of thrombin2,34,35. 
Efforts to stabilize the D-Phe-Pro-Arg-H sequence against degradation to a heterocyclic 
compound in solution led to synthesis of tripeptides with N-terminal protecting groups4,35. 
Significantly, use of a tert-butoxycarbonyl protecting group resulted in a compound that 
inhibits plasmin and thrombin equally well. In subsequent study, the N-terminus was found 
to be most amenable to thrombin specificity with a basic moiety, with Bajusz et al. 
determining the D-MePhe-Pro-Arg-H N-methyl derivative to match the specificity and 
affinity of D-Phe-Pro-Arg-H while introducing highly enhanced stability34.  
PPACK 
D-phenylalyl-L-prolyl-L-arginyl-chloromethyl ketone (PPACK) is a highly effective 
irreversible thrombin inhibitor with sub-nanomolar affinity for thrombin and several orders 
of magnitude lower affinity for similar proteases2,4,15,16,36. As an affinity label, PPACK in 
complex with thrombin has a well-characterized stable structure4,15,16. The molecule also 
exhibits an excellent safety profile for use in vivo, with an LD50 greater than 50 mg/kg and 
no long-term toxicity in mice2,37. Likewise, no toxic side effects were evident in rabbits, 
cats, and baboons at therapeutically relevant doses. Dose-dependent prolongation of 
partial thromboplastin time and prothrombin time was observed in vivo in various 
species2,37-40.  
Different models have also shown the potential utility of PPACK as an inhibitor in 
various therapeutic situations. Of note, PPACK inhibited aortic thrombi in rabbits2. An 
effect on reocclusion was also observed in rabbits, where new thrombi could not form in 
7 
the presence of PPACK after thrombolytic treatment2. In baboons, hemostatic plugs and 
occlusion of vascular grafts and endovascular stents was inhibited2. In rats, hemostasis in 
the jugular vein was prevented and thrombolysis by tissue plasminogen activator was 
enhanced by the introduction of PPACK2.   
Therapeutic use of irreversible thrombin inhibitors like PPACK has been for the most 
part abandoned. Concerns regarding the specificity and stability of irreversible covalent 
thrombin inhibitors persist3. Nonetheless, the structure of the thrombin-PPACK complex 
has been completely characterized as a permanent association4,15,16 and the specificity of 
PPACK for thrombin is well known2,36. Furthermore, it has been shown that instability of 
the Phe-Pro-Arg sequence via cyclization in vivo can be alleviated through protection of 
the N-terminus of the peptide. As noted, N-methyl protection allowed the sequence to 
maintain affinity and specificity for thrombin34,35. In this light, the most unambiguous 
drawback to therapeutic use of PPACK is its rapid clearance (0.7 minute distribution and 
2.9 minute elimination half lives), which necessitates continuous infusion for effective 
treatment2,37. 
BIVALIRUDIN 
Bivalirudin is a parenteral anticoagulant derived from the naturally occurring leach 
saliva anticoagulant, hirudin. The 20 amino acid bivalirudin sequence is a homologue to 
the portion of hirudin binding concurrently to exosite I and the catalytic site of alpha 
thrombin32. The bivalent mode of direct inhibition confers great specificity to thrombin. On 
binding, bivalirudin is cleaved by thrombin at the catalytic site and releases in a largely 
inactive form following cleavage33. Of note, its activity against clot-bound thrombin is 
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identical to that against circulating thrombin32. Additionally, it has exhibited ability to control 
platelet activation and aggregation41,42. Renal clearance eliminates bivalirudin from the 
blood with a normal half-life of 25 minutes33. It has received clinical approval and is 
indicated as an alternative to ultrafractionated heparin in percutaneous coronary 
intervention. Given its strong safety profile and demonstrated versatility for thrombin 
inhibition, bivalirudin is under investigation as an anticoagulant for application in different 
acute thrombotic disorders33,41,42. 
PERFLUOROCARBON NANOPARTICLES 
Perfluorocarbon (PFC) emulsions comprise nanoparticles consisting of a liquid 
perfluorocarbon core surrounded by a lipid-surfactant monolayer. The phospholipids 
stabilize the core and confer stability on the construct. Intravenously administered PFC 
emulsions have a long history of use as blood substitutes and ultrasonic contrast agents43. 
PFC nanoparticles can also be modified chemically to achieve targeted drug delivery 
enabled by their large capacity for surface functionalization with targeting ligands and 
therapeutic agents44-46. Given large numbers of therapeutic molecules, vascular 
confinement, and the possibility of site-specific targeting, PFC nanoparticles are capable of 
concentrated therapeutic impact with minimal toxicity to peripheral tissues.  
PFC nanoparticles have been employed for a wide range of applications in drug 
delivery and imaging44-47. In previous work, PFC nanoparticles have been employed for 
magnetic resonance, optical, ultrasound, and SPECT contrast44,48-50. In particular, imaging 
and spectroscopy have been used to locate and quantify nanoparticle accumulation in vivo 
as part of therapeutic applications51. PFC emulsions have a long history of safe use in 
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blood transfusions43 The anticipated nanoparticle distribution and elimination half-lives 
(approximately ten minutes and three hours, respectively) control the duration of 
therapeutic activity for nanoparticles functionalized with drugs48,43.  
 
1.3   Significance 
There is a clear need for new potent and highly specific antithrombotic agents with 
minimal toxicity for the treatment of thrombosis in acute coronary syndromes9-11, stroke12, 
venous thrombosis10,13, and stent placement52,53. The primary medical application for the 
nanoparticle thrombin inhibitors proposed here would be in acute rather than in chronic 
treatment, for which the challenge of developing a safe and effective oral anticoagulant to 
replace warfarin remains. 
To this end, aims #1-4 will produce therapeutically active nanoparticles with inherent 
specificity for proliferating thrombi and minimal off-target effects. Several unique 
advantages are inherent to the nanoparticle-based thrombin inhibitor. First, the base PFC 
nanoparticle manifests predictable and advantageous pharmacokinetics. Second, unlike 
soluble thrombin inhibitors, the nanoparticle intrinsically concentrates the active 
pharmaceutical on a lipidic surface to elicit the local suppression of thrombin. Each particle 
will carry ~10000 thrombin inhibitors, so we anticipate that a particle at the site of 
thrombus formation might exert a greater impact than a typical soluble inhibitor, such as 
heparin. Third, the particles, when retained at or around a thrombus, will constitute 
antithrombotic surfaces, acting as “thrombin sponges,” that can disable active thrombin in 
a prothrombotic milieu. Finally, as explored in aim #5, the particle will enable image-based 
10 
confirmation of drug delivery, in turn permitting tracking of its therapeutic activity. 
Continued expansions on aims #1-4 with different types of thrombin inhibitor moieties may 
allow more cost effective and efficient treatment of thrombosis. Towards realistic 
implementation of the novel antithrombotics developed in aims #1-4, future work may be 
aimed towards implementation in models for atherosclerotic plaque rupture24,25,54-56, acute 
kidney injury57, or arterial graft installation58. Implementation of antithrombotic 
nanoparticles in various disease models will contribute to demonstrating the developing 
clinical utility of thrombin-inhibiting nanoparticles. 
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Chapter 2 
 
PPACK Perfluorocarbon Nanoparticles as a First Demonstration of a Nanoparticle 
Antithrombotic Agent  
 
2.1   Introduction 
Towards addressing the need for novel agents that promote pharmaceutical control of 
thrombosis in acute vascular syndromes1-12, we hypothesized that inherently anticoagulant 
nanoparticulate structures could offer a safer and more efficacious platform for localized 
antithrombotic action, with potential to simultaneously provide a means to detect an acute 
thrombotic event in a culprit artery or vein due to their ability to be imaged13,14. Although 
nanoparticles have been suggested as a means of conveying common anticoagulants to 
vascular segments15, it has not been shown that they would function as effective 
antithrombotics in vivo.  Here, a perfluorocarbon-core (PFC) nanoparticle16,17 is 
demonstrated as an integrated antithrombotic where the nanoparticle itself plays a critical 
role in preventing coagulation by presenting thrombin-absorbing surfaces at the site of 
vascular injury.  
The central role of thrombin as a rate-limiting factor in clotting and platelet activation12,18-
24 motivated the design of an anticoagulant nanoparticle that could achieve high affinity 
molecular targeting of thrombin at sites of acute thrombosis. The nanoparticle surface is 
activated against thrombin by permanent covalent attachment of D-phenylalanyl-L-prolyl-L-
arginyl-chloromethyl ketone (PPACK), a highly effective irreversible thrombin inhibitor with 
sub-nanomolar affinity for thrombin and several orders of magnitude lower affinity for 
similar proteases10,12,18,19,25. As noted in the introductory section, PPACK in complex with 
thrombin has a well-characterized stable structure12,18,19. It has an excellent safety profile 
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in vivo, with an LD50 greater than 50 mg/kg and no long-term toxicity in mice10,26, but its 
pharmacokinetics are unfavorable for antithrombotic use in vivo due to rapid elimination 
(~3 minutes half-life).  
Thus, the present antithrombotic nanoparticle was designed to manifest prolonged 
local bioactivity against clotting, in the face of very rapid attenuation of systemic 
anticoagulation to achieve an improved safety profile. The data will indicate that the 
PPACK particle targets to sites of activated thrombin, resulting in site-targeted inhibition of 
uncontrolled clotting. 
 
2.2   Methods 
Nanoparticle Synthesis 
PFC nanoparticles were prepared as described in previous work27. The emulsions 
contained 20% (vol/vol) Perfluoro 15-Crown-5 Ether (Exfluor Research Corp.), 2% (wt/vol) 
of a surfactant mixture, 1.7% (wt/vol) glycerin, and water for the balance. The surfactant, 
including 98.5 mole% phosphatidylethanolamine (Avanti Polar Lipids) and 1.5 mole% 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] 
(Avanti Polar Lipids) or 98 mole% egg yolk phosphotidylcholine (Avanti Polar Lipids) and 2 
mole% phosphatidylethanolamine (Avanti Polar Lipids) in chloroform:methanol (3:1), was 
dried under vacuum to form a lipid film. The surfactant components were combined with 
the crown ether and distilled de-ionized water, and emulsified (Microfluidics Inc) at 20000 
psi for 4 minutes. Particle sizes were measured immediately after synthesis using a laser 
light scattering submicron particle analyzer (Brookhaven Instruments). 
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Amine-carboxyl coupling was employed to functionalize particles containing 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000]  with 
PPACK. After one hour mixing of 1 mL emulsion with 12.5 mg PPACK, EDCI 1-[3-
(Dimethylamino)propyl]-3-ethylcarbodiimide methiodide (2 mg) was added for overnight 
coupling. Excess PPACK and EDCI was removed by dialysis (MWCO 3000-5000). Particle 
size was assessed before and after PPACK conjugation. Extent of PPACK coupling was 
determined by reverse-phase HPLC quantification of uncoupled PPACK after 
centrifugation of nanoparticles with Cleanascite lipid adsorption reagent (Agilent 
Technologies). Elution of PPACK in a C18 column was achieved with an isocratic method 
employing 9.9% acetonitrile, .089% trifluoroacetic acid, and 90.011% water. PPACK was 
detected via phenylalanine absorbance (258 nm). Zeta potential measurements were used 
for further verification of PPACK coupling (Brookhaven Instruments). 
Thrombin Inhibition Experiments 
 Tosyl-Gly-Pro-Arg-4 nitranilide acetate (Chromozym TH, Roche Applied Science) 
assay assessed PPACK inhibition of thrombin and plasmin in accordance with previously 
described methods28. 100 mL of 12 nM thrombin was incubated for one minute at room 
temperature with selected amounts of PPACK or PPACK-nanoparticles or with an excess 
of bare nanoparticles. 500 mL (100 mM) of Chromozym TH thrombin substrate were 
added to terminate the PPACK-thrombin interaction. Thrombin activity against the 
substrate was measured via absorbance at 405 nm. The rate of change in absorbance at 
405 nm indicated the amount of thrombin available to cleave Chromozym TH.  
20 
 Chromozym TH assay was used to determine the kinetics of the PPACK-thrombin 
interaction. .92 nM thrombin was incubated at room temperature with 5 nM PPACK or .3 
pM PPACK nanoparticles over various times prior to introduction of 500 mL of 100 mM 
Chromozym TH. Thrombin activity was measured as above. Kinetics of inhibition were 
characterized in accordance with the work of Kettner and Shaw29. The assay yielded the 
apparent pseudo-first-order rate constant for thrombin inactivation (kapp). Modeling 
inhibition according to equation (1), estimates of the second order constants (k2/Ki) for the 
PPACK-thrombin interaction and the PPACK nanoparticle-thrombin interaction were 
obtained via equation (2) following a linear fit to log(activity) versus time data to determine 
kapp. To best obtain a pseudo-first-order reaction, thrombin dilution was maximized within 
the limits set by the sensitivity of the Chromozym TH assay.  
             (1)  
                                                                (2) 
 Chromozym TH was also used to measure PPACK and PPACK nanoparticle activity 
against plasmin. 120 nM Plasmin was incubated for three minutes at room temperature 
with PPACK or PPACK nanoparticles. 1000-fold excess (138 mM) of PPACK (free or on 
nanoparticles) was employed to produce a measurable effect on plasmin activity against 
Chromozym TH. Activity after incubation with PPACK and PPACK nanoparticles was 
compared. 
Antithrombotic Effects In Vivo 
 All animal experiments were approved by the Washington University Animal Care and 
Use Committee and are based on National Institute of Health laboratory standards. 
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Following methods described in previous work28,30, 10-12 week old male C57BL/6 mice 
(weight 25-30 g) were subjected to photochemical injury of the carotid artery. After 
anesthetization with sodium pentobarbital, the mice were secured under a dissecting 
microscope for isolation of the right common carotid artery via midline cervical incision. An 
ultrasonic flow probe (model 0.5 VB Transonic Systems, Ithaca, NY) was applied to the 
artery to measure flow for the duration of each experiment. A 1.5 mW 540 nm HeNe laser 
(Melles Griot, Carlsbad, CA) was focused on the artery at a distance of 6 cm. Heparin 
(.125 mg/kg, n=4), PPACK (12.5 mg/kg, n=7), PPACK nanoparticles (1 mL/kg, n=7), or 
non-functionalized nanoparticles (1 mL/kg, n=7) were administered to the tail vein as a 
bolus 10 minutes prior to inducing arterial thrombus through tail vein injection of 
photosensitive rose bengal dye (50 mg/kg; Fisher Scientific, Fair Lawn, NJ) dissolved in 
PBS. In additional control experiments (n=4), no treatment preceded injection of the rose 
bengal dye. Occlusion of the carotid artery was noted and experiments were terminated 
upon the stable (>5 minutes) maintenance of zero flow.  
 Occluded arteries were removed and preserved. For transmission electron microscopy, 
arteries were fixed in 2% glutaraldehyde and 0.1 mM sodium cacodylate at 4 degrees. 
Fixed tissues were stained with osmium tetroxide, tannic acid, and uranyl acetate. Tissues 
were then dehydrated and embedded in PolyBed 812 (Polysciences). Semi-thin sections 
were stained with Toluidine Blue and evaluated under light microscope for the presence of 
occlusive clotting. Portions of arteries identified as containing thrombi were subsequently 
sliced for transmission electron microscopy. Thin sections were counterstained with uranyl 
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acetate and lead citrate. Samples were examined with a Zeiss 902 Electron Microscope 
and images were recorded with Kodak EM film.  
For Carstair’s staining to identify platelets and fibrin, arteries were preserved in 10% 
buffered formalin for 3 days. After processing through alcohols and xylenes, the arteries 
were embedded in paraffin and sectioned at 5-micron thickness. Hydrated sections were 
treated with 5% ferric alum, Mayer’s hematoxylin, picric acid-orange G solution, poncean-
fuchsin solution, 1% phosphotungstic acid, and aniline blue to stain for fibrin, platelets, 
collagen, muscle, and red blood cells. Images were analyzed for platelet content using 
ImageJ.  
In additional mice, APTTs for blood obtained via left-ventricular draws were used to 
determine the systemic effects of the particles. Citrate-anticoagulated blood was obtained 
10, 20, 40, 70, 110, or 150 minutes after injection of a bolus of PPACK nanoparticles or 10 
minutes after injection of control nanoparticles or saline. Plasma was combined with APTT 
reagent (Beckman-Coulter/Instrumentation Laboratory) for three minutes prior to activation 
with calcium chloride and mechanical determination of coagulation time. 
Statistics 
 Significance levels were determined by two-tailed two-sample unequal variance T-
tests. Error bars denoted standard error. Data fitting employed an iterative least-squares 
algorithm. 
 
2.3   Results 
Nanoparticle Synthesis 
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 PFC nanoparticles were synthesized with inclusion of carboxy-terminated PEG capped 
lipids (Fig. 1). Via EDCI coupling, amide bonds were formed between the N-terminus of 
PPACK and the bare carboxyls on the particle surface. After conjugation of PPACK, 
nanoparticles were examined to verify stability. Precursor nanoparticles, were found via 
laser scattering to have a hydrodynamic diameter of 158.0 ± 2.4 nm. PPACK nanoparticles 
had a measured diameter of 160.5 0 ± 2.6 nm (Fig. 2).  
After PPACK coupling, a change in the composition of the lipid surface of the particles 
was evident via measurement of zeta potential. Prior to PPACK coupling, the particles   
exhibited a zeta potential of -35 0 ± 1.57 mV. After addition of PPACK, the zeta potential 
rose to -22.3 ± 1.57 mV, concordant with the expectation that the PPACK arginine would 
reduce the negative zeta potential of the non-functionalized nanoemulsions (Fig. 2).  
 Following synthesis but before dialysis to remove PPACK that did not couple to the 
particles, the residual uncoupled PPACK in the emulsion was quantified by reverse phase 
liquid chromatography. For PPACK nanoparticles not subject to dialysis, HPLC analysis 
indicated approximately 13650 PPACK coupled to each particle. HPLC also determined 
the amount of PPACK not associated with the particles after dialysis and one week 
storage at four degrees, indicating of the good stability of the PPACK nanoparticle 
formulation (Fig. 3).  
Thrombin Inhibition: Kinetics and Specificity 
 PPACK and PPACK nanoparticle inhibition of thrombin was evaluated by measuring 
thrombin activity on the chromogenic substrate, Chromozym TH. After one-minute  
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Figure 2.1 Schematic of the PPACK-functionalized PFC-core nanoparticle (a). The 
majority of the phospholipid monolayer comprised an egg lecithin L-α-
phosphatidylethanolamine layer.  1% of the lipid film was 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000], functionalized with PPACK 
after particle synthesis (b). 
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Figure 2.2 Particle size was measured before and after addition of PPACK to 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] in the 
lipid film. The addition of PPACK did not significantly change the mean hydrodynamic 
particle diameter of 158.0 ± 2.4 nm (top panel). Corresponding to conjugation of positively 
charged PPACK to carboxy-terminated lipids, the particle zeta potential rose from -35 ± 
1.57 mV to -22.3 ± 1.57 mV after functionalization. 
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Figure 2.3 Addition of ~13650 PPACK per particle was verified through HPLC 
quantification. The PPACK elution time for the chosen method was identified in seven 
samples of pure PPACK of different concentrations to generate a standard curve. 
Immediately after coupling of PPACK to the particles, the particles were precipitated and 
PPACK in the supernatant was quantified through the same method (red). Free PPACK 
and EDCI coupling agent were removed by dialysis and the isolated particles were 
precipitated identically after one week storage at 4 degrees, allowing quantification of 
PPACK still remaining unattached to the particles (blue).  
 
 
 
 
 
 
 
  
 
 
 
 
27 
incubation with either PPACK nanoparticles or free PPACK, thrombin activity against the 
substrate decreased monotonically with increasing inhibitor concentration (Fig. 4a). 
PPACK on the nanoparticles gave a decay constant of 0.033 nM-1 and free PPACK gave a 
decay constant of .026 nM-1, indicating no diminution of PPACK activity after conjugation 
to particles. Complete inhibition of thrombin activity was achieved at a 15.5 pM particle 
concentration, corresponding to deactivation of approximately 1000 thrombin by each 
particle.  
 Chromozym TH assay also defined the kinetics of PPACK and PPACK nanoparticle 
inhibition of thrombin in accordance with the model of Kettner and Shaw (Fig. 4b). For free 
PPACK, the pseudo-first-order rate constant, kapp, was measured as 1.824 min-1. The 
second order constant for free PPACK was approximated as kapp/[PPACK] = 3.65x108 M-
1min-1 (whereas Kettner and Shaw originally found a constant of 1.20x109 M-1min-1)29. 
PPACK on the nanoparticles exhibited a kapp of 1.848 min-1 and a second order constant of 
4.47x108 M-1min-1. The PPACK nanoparticle, considered as an inhibitor itself, exhibited a 
second order constant of 6.10x1012 M-1min-1. PPACK nanoparticles at the site of 
thrombotic injury thus have a kinetic advantage over free PPACK in the inhibition of 
thrombus formation. Furthermore, the kinetics of the PPACK-thrombin interaction showed 
no significant alteration with PPACK bound to nanoparticles. Without PPACK, the 
nanoparticles had no effect on thrombin activity. To further explain the kinetics of PPACK 
nanoparticle activity against thrombin, both in solution and bound to a surface, a physically 
meaningful mechanistic model is developed in appendix 2. 
 Chromozym TH was used to test the response of plasmin activity to PPACK and  
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Figure 2.4 PPACK caused concentration-dependent inhibition of thrombin activity against 
Chromozym TH. For PPACK-nanoparticles, the dependence of thrombin activity on 
PPACK concentration was identical to that for free PPACK, accordingly indicating greater 
antithrombin activity per particle than per individual free PPACK (a). Study of the kinetics 
of thrombin inhibition indicated no modification to PPACK activity against thrombin after 
placement on nanoparticles (b). For 0.93 nM thrombin and 5 nM PPACK (0.0003 nM 
PPACK-nanoparticles), PPACK exhibited a second order constant (k2/KI) of 3.65x108 M-
1min-1 and PPACK-nanoparticles exhibited a second order constant of 6.10x1012 M-1min-1 
(corresponding to 4.47x108 M-1min-1 for PPACK on the particles). 
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PPACK nanoparticles (Fig. 5). Greater than 80% inhibition of plasmin activity against 
Chromozym TH was achieved with 138 µM PPACK, both for free PPACK and particle-
bound inhibitor. Conjugation of PPACK to nanoparticles constitutes an N-terminal 
modification to the inhibitor that does not compromise its specificity for thrombin over 
plasmin.  
Antithombotic Efficacy in vivo  
In trials of the in vivo effect of PPACK nanoparticles, thrombotic occlusion of the carotid 
artery was induced in C57BL/6 mice. Blood flow in the carotid artery steadily diminished as 
occlusion progressed (Fig. 6). Time to occlusion indicated efficacy of fibrin and platelet 
deposition. Saline, heparin, non-functionalized nanoparticles, PPACK, or PPACK 
nanoparticles were administered ten minutes before inducing laser injury via injection of 
rose bengal dye (Fig. 7a). With saline sham treatment, carotid artery occlusion occurred at 
70 ± 17 minutes after dye injection. Following a bolus of control nanoparticles, occlusion 
occurred at 66 ± 14 minutes. PPACK alone, despite its efficacy as a thrombin inhibitor in 
vitro, also exerted no apparent impact on thrombus formation in vivo, resulting in a mean 
occlusion time of 71 ± 19 minutes. The absence of an antithrombotic effect for PPACK 
accords with the expectation of a 2.9-minute reported clearance half-life and with the 
known in vivo instability of PPACK without protection of the N-terminus.  
Heparin, however, has well-characterized antithrombotic effects and is a standard 
option as an anticoagulant for mediation of acute thrombus formation. Previous trials with 
the rose bengal thrombosis model yielded an occlusion time of 97 ± 18 minutes for heparin 
at a dose of 0.125 mg/kg animal weight28. Here, occlusion occurred at 102 ± 13 minutes  
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Figure 2.5 PPACK and PPACK-nanoparticle activity against plasmin was tested via 
assessment of plasmin activity against Chromozym TH. A 1000-fold excess of PPACK 
generated 85% suppression of plasmin activity (red). Conjugation of PPACK to 
nanoparticles (blue) generated no additional non-specific activity against plasmin. 
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Figure 2.6 Photochemical injury was used to induce thrombotic occlusion of the mouse 
carotid artery while monitoring blood flow. Representative blood flow time courses for 
animals treated with PPACK (red), heparin (black), or PPACK-nanoparticles (blue) are 
depicted. In the presence of PPACK-nanoparticles or heparin, formation of a stable 
thrombus was noticeably delayed, whereas free PPACK allowed a steady approach to 
complete occlusion. The PPACK time course was largely indistinguishable from a control 
time course (grey). 
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Figure 2.7 Mean ± standard deviation occlusion time for each tested treatment condition in 
photochemical thrombotic injury experiments. Treatment with PPACK (n=7) or non-
functionalized nanoparticles (n=7) did not delay occlusion time. PPACK-nanoparticle 
treatment more than doubled occlusion time over PPACK-treated (p=0.0006) or non-
treated mice (n=7). PPACK-nanoparticle treatment also lengthened occlusion time relative 
to heparin treatment (p=0.001, n=4) (a). In blood draws, PPACK nanoparticles delayed the 
APTT only briefly, with systemic coagulation times approaching control values over the 
first 20 minutes after injection (b). 
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(Fig. 7a).  
Occlusion time more than doubled to 145 ± 13 minutes in the mice treated with a 1 
ml/kg dose of PPACK nanoemulsion (in which the administered amount of PPACK was 
less than that given for trials of the free inhibitor) (Fig. 7a). As compared to a high dose of 
heparin, PPACK nanoparticles outperformed (p<0.001) the established anticoagulant. 
Likewise, both PPACK nanoparticles (p<0.001) and heparin (p<.05) extended time to 
occlusion of the carotid over PPACK treatment.   
Activated partial thromboplastin time (APTT) for treatment with control nanoparticles did 
not significantly differ from APTT for saline treatment. At 10 minutes after injection of 
PPACK nanoparticles, coagulation time was significantly lengthened. However, blood 
withdrawn at 20 minutes after injection nearly matched control APTT values. Subsequent 
blood draws yielded APTTs that did not significantly differ from control values (Fig. 7b), 
indicating fast abatement of the systemic effects of the PPACK particles despite prolonged 
therapeutic effect. A similar time course was evident in preliminary measurements of 
bleeding times in the tail after administration of PPACK nanoparticles as a tail vein bolus 
(Fig. 8).  
 To further elucidate the mechanism by which PPACK nanoparticles prevent thrombus 
formation, TEM was used to examine the microstructure of fully formed thrombi. In clots 
formed after treatment with PPACK nanoparticles, few degranulated platelets were 
observed. Furthermore, platelets in such clots were loosely associated with one another, 
showing no signs of the dense packing evident in well-formed platelet aggregates. Instead, 
a fibrin gel appeared to dominate the clot microstructure (Fig. 9a). In TEM images of clots  
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Figure 2.8 Bleeding times were measured via distal tail injury at selected times after tail 
vein bolus of PPACK nanoparticles at 1 ml/kg. All depicted data are for n=1. 
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Figure 2.9 TEM was used to characterize microstructure of excised clots formed during 
PPACK nanoparticle or control nanoparticle treatment. Clots formed in the presence of 
PPACK-nanoparticles had loosely associated platelets with little evidence of degranulation 
(a). Close association, degranulation, and interdigitation of platelets was evident in clots 
formed in the presence of control nanoparticles (b). 
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subject to control nanoparticle treatment, close association and interdigitation of platelets 
was evident. Similarly, degranulated platelets were abundant in these thrombi (Fig. 9b).  
 Carstair’s staining was used to assess relative amounts of platelets and fibrin in 
selected clots. Staining of clots formed after PPACK nanoparticle treatment indicated a 
predominance of fibrin with only sparse clusters of platelets (Fig. 10). For clots formed in 
the presence of control nanoparticles, platelet staining was denser and interconnected 
(taking up 7.28% of clot area as opposed to 1.66% in PPACK-treated clots) (Fig. 11). 
 
2.4   Discussion 
Prior work has defined the pharmacokinetics of functionalized PFC nanoparticles for 
drug delivery and imaging applications (see Appendix 1)16,31. Based on these studies and 
the long clinical history of PFC use as a blood substitute, the in vivo safety and stability of 
the base PFC emulsion has been established. Stable attachment of covalently bound 
targeting ligands has also been demonstrated for this class of agents32-34. Building on this 
platform, the PPACK nanoparticle was designed as a direct thrombin inhibitor presenting a 
thrombin-absorbing surface that is bound and retained at a site of acute thrombosis. 
Although PPACK itself is not clinically useful as an antithrombotic10,35, the PPACK PFC 
nanoparticle is an effective anticoagulant due to apparent sequestration of numerous 
PPACK ligands at the site of thrombosis that continue to maintain prolonged surveillance 
against any subsequently activated thrombin after the initial binding event (see Appendix 
1). 
To demonstrate efficacy of the PPACK particle in vivo, the rose bengal thrombosis 
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Figure 2.10 Carstair’s staining of clots subject to treatment with PPACK nanoparticles (a) 
or control nanoparticles (b) helped to examine the nature of the clots formed with each 
treatment. Clots formed in the presence of PPACK nanoparticles exhibited sparse staining 
of platelets (blue in the central region) and large amounts of isolated fibrin (pink in the 
central region) (a). With control nanoparticle treatment, staining of platelets was more 
prominent (b). Endothelium is artifactually lifted away from the thrombus.  
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Figure 2.11 Area occupied by platelet staining within Carstair’s stained thrombi was 
evaluated in NIH ImageJ. For three arteries treated with control nanoparticles, platelet 
staining occupied 7.28%±2.87% of thrombus area. For three arteries treated with PPACK 
nanoparticles, platelet staining occupied 1.66%±.18% of thrombus area.  
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model was chosen based on its known sensitivity to a wide range of anticoagulants. The 
standardized metric of “time to arterial occlusion” in this model has been used to examine 
the potency of other notable thrombin inhibitors30. We demonstrate that the PPACK 
nanoparticle can delay localized occlusive thrombosis in this model while rapidly 
minimizing systemic effects on bleeding times, and indeed appears more effective than a 
selected conventional anticlotting agent.  Although PPACK is used as the active 
pharmaceutical ingredient in this case, the antithrombotic nanoparticle acts as a unique 
inhibitor in its own right regardless of the drug that is conjugated to the particle. Rather 
than serving simply as a vehicle that delivers and releases an antagonist to the thrombin 
target, the particle holds onto the inhibitor and acts against thrombus formation by 
maintaining localized thrombin-absorbing surfaces that are not disabled after locating a 
thrombin target. 
Our analysis of thrombotic occlusions formed in the presence of PPACK particles 
indicates that, as part of its therapeutic impact, the antithrombotic particle also impacts 
platelet deposition. The particle likely inhibits thrombin’s ability to activate platelets via 
PAR cleavage19-23. As evaluated with Carstair’s staining (Fig. 5s) and with TEM (Fig. 5), 
the morphology of the clots formed after PPACK particle treatment is distinguished by 
sparse platelet distribution and reduced density of packing. The apparent reduction in 
platelet deposition in our treatment suggests a possible broader clinical application for this 
particle platform as a combined antithrombotic and antiplatelet agent. Identification of the 
pathways through which the particles act against platelet activation and aggregation is a 
question of interest for future work. 
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The clinical introduction of specific and potent direct thrombin inhibitors has garnered 
attention in recent years. PPACK, though ineffective as an isolated molecule, was used 
here as a reasonably cheap, small, and non-toxic35 agent to complex with PFC 
nanoparticles. However, other known thrombin inhibitors could be employed with the use 
of conventional and flexible conjugation schemes, given that diphospholipids with large 
varieties of linking groups and spacers are readily available commercially. As explored in 
chapter 3, the PFC nanoparticle thrombin inhibitor model is hypothesized to retain its 
noted advantages (including the ability to form antithrombotic surfaces) with adaptation to 
different inhibitory moieties. A theoretical framework for investigation of other selected 
inhibitors, various inhibitor loadings, and particle dose dependencies is established in 
appendix 2 to enable further studies to advance the antithrombotic nanoparticle towards 
clinical use. More thorough investigation of the systemic effects of antithrombotic 
nanoparticles, including prothrombin time, thrombin time, platelet aggregometry, and 
further bleeding tests, is left for further work. 
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Chapter 3 
 
Bivalirudin Nanoparticles Demonstrate Versatility and Efficacy of Thrombin-
Inhibiting Nanoparticles as Site-Specific Antithrombotic Agents 
 
3.1   Introduction 
 
To address the pharmaceutical use of direct thrombin inhibition to control acute or 
chronic vascular events1-7, the work described in chapter 2 develops a prototypical 
antithrombotic nanoparticle (NP) system functionalized with the known direct thrombin 
inhibitor, D-Phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone (PPACK), which presents 
a potent and sustainable anti-clotting surface at sites of acute thrombosis8.  This system is 
designed explicitly for acute use, and exhibits unique features of rapid onset, prolonged 
inhibitory bioactivity at the site of acute clotting (hours), rapid diminution of systemic 
anticoagulation (within 30 minutes), and a capacity for detecting acute thrombotic events 
by magnetic resonance imaging of the NPs9 that are bound to active thrombin at the site of 
ongoing clotting.  However, two theoretical drawbacks of the prototypical design required 
further modification and testing: the irreversible inhibition of thrombin by PPACK10, and its 
lack of specificity for thrombin versus other serine proteases11. The work in this chapter 
proposes and demonstrates a second NP antithrombotic agent that incorporates the highly 
specific, reversible, and clinically approved inhibitor, bivalirudin, and compares its 
functionality against conventional agents and the original PPACK-NP system. 
Bivalirudin exhibits anticoagulant properties derived from superior specificity for active 
thrombin12 and activity against clot-bound thrombin13. It can serve as an anticoagulant 
complexed with a NP without significant modification of its native structure. This chapter 
illustrates that bivalirudin NPs outperform free bivalirudin itself in preventing occlusive 
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thrombus formation, and shows that bivalirudin NPs match bivalirudin’s known activity 
against thrombin that is already bound in clots. Bound to the surface of clots, the 
bivalirudin NPs show the ability to prevent further clotting induced by a prothrombotic 
surface. Furthermore, the system offers an approach for detecting acute thrombosis by 
serving as an MRI contrast agent with a unique fluorine spectral signature. The results 
suggest that a clinically utile thrombin inhibitor such as bivalirudin can be improved in 
terms of potency and safety by incorporation into an antithrombotic NP capable of binding 
at sites of active thrombosis.  
 
3.2   Methods 
Formulation of Bivalirudin-Functionalized PFC Nanoparticles 
PFC emulsions contained 20% (vol/vol) Perfluoro 15-Crown-5 Ether (Exfluor Research 
Corp.), 2% (wt/vol) of a surfactant mixture, 1.7% (wt/vol) glycerin, and water for the 
balance. The surfactant contained 99 mole% phosphatidylethanolamine (Avanti Polar 
Lipids) and 1 mole% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethylene glycol)-2000] (Avanti Polar Lipids) in chloroform:methanol (3:1). The 
surfactant was dried under vacuum to form a lipid film, which was then combined with the 
other nanoemulsion components, and emulsified (Microfluidics Inc) at 20000 psi for 4 
minutes. Particle sizes were measured following emulsification with the use of a laser light 
scattering submicron particle analyzer (Brookhaven Instruments)14. 
Amide formation via carbodiimide was employed to functionalize particles containing 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] 
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with bivalirudin. After 1 mL emulsion with 40 mg bivalirudin (Bachem California) for one 
hour, EDCI 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide methiodide (2 mg) was added 
and incubated overnight to achieve coupling. Excess bivalirudin and EDCI were removed 
by overnight dialysis (molecular weight cutoff 3000-5000 g/mol). Particle size was 
assessed before and after bivalirudin conjugation.  
The extent of bivalirudin coupling was determined by optical quantification of uncoupled 
bivalirudin after centrifugation of NPs (1000 gs for 15 minutes) prior to dialysis with 
Cleanascite lipid adsorption reagent (Agilent Technologies). Bivalirudin was detected in 
the supernatant via tyrosine fluorescence (absorbance 274 nm, emission 303 nm) (Varian) 
and quantified by comparison to fluorescence from bivalirudin standards. Zeta potential 
measurements were used for further verification of bivalirudin coupling (Brookhaven 
Instruments).  
Characterization of Thrombin Inhibition by Bivalirudin Nanoparticles 
Tosyl-Gly-Pro-Arg-4 nitranilide acetate (Chromozym TH, Roche Applied Science) 
assay assessed bivalirudin inhibition of thrombin in accordance with previously described 
methods15. 100 µL of 12 nmol/L thrombin in 1.0M Tris buffer was incubated for one minute 
at room temperature with selected amounts of bivalirudin or bivalirudin NPs (n=3 for each 
concentration). 500 µL (100 µmol/L) of Chromozym TH thrombin substrate in 1.0 mol/L 
Tris buffer was added to terminate the bivalirudin-thrombin interaction. Thrombin activity 
against the substrate was measured via absorbance at 405 nm. The rate of change in 
absorbance at 405 nm indicated the rate at which thrombin cleaved Chromozym TH. A 
model appropriate to tight-binding reversible inhibitors like bivalirudin was employed to 
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analyze the Chromozym TH data (equations 1 and 2). Following the methods of Stone and 
Hofsteenge16, the model permitted measurement of effective KI values for bivalirudin and 
bivalirudin on NPs. For comparison, the model was also applied to data for PPACK, 
presented in chapter 2. 
  (1) 
 
 (2)  
In equation (2), the inhibition reaction velocity in the absence of inhibitor is v0, the total 
thrombin concentration is Et, the steady state (one minute) velocity for inhibitor 
concentration It is vs, and KI’ is the effective inhibition equilibrium constant for a given 
Chromozym TH concentration S and substrate-thrombin equilibrium constant Km.  
Characterization of Clot-Bound Thrombin Inhibition 
Fibrinopeptide A (FPA) ELISA (American Diagnostica GmbH) was used to measure 
fibrin generation by thrombin in human plasma or bound in human plasma clots. To assess 
the PPACK, bivalirudin, PPACK NP8, or bivalirudin NP efficacy against activity of clot-
bound or free thrombin, the methods of Weitz et al. were employed to quantify fibrin 
generation by thrombin both bound in clots and free in plasma13.  
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Human plasma was incubated at 37° C for one hour with selected quantities of 
thrombin or inhibitor. After incubation, plasma was twice washed with bentonite and 
centrifuged at 2500g for 20 minutes to remove fibrinogen while leaving FPA produced by 
thrombin. After addition of 2% Tween 20 (5% vol/vol) to the bentonite-treated plasma, FPA 
antibody with no demonstrable cross reactivity to fibrinogen or homologous fragments of 
fibrinogen was introduced for incubation at 37° C for one hour. The antibody-treated 
plasma was introduced to FPA-coated wells for a one-hour incubation at room 
temperature. After five washes, a secondary antibody complexed with horseradish 
peroxidase (HRP) was introduced for incubation at room temperature for one hour. After 
five additional washes, substrate to the HRP was added to the wells. Digestion of the 
substrate was concluded after 5 minutes with addition of 0.45 mol/L H2SO4. The 
absorbance at 450 nm for the substrate/H2SO4 solution was measured with a plate reader 
(Bio-Rad). The resulting absorbance values were indirectly proportional to the quantity of 
FPA in the plasma samples, allowing FPA concentration and thus thrombin activity in the 
plasma samples to be determined by comparison with FPA standards provided by the 
assay manufacturer.  
In additional experiments to test the inhibitory potential of the NP system against clot-
bound thrombin, fibrin clots were formed by mixing 563 µL citrated human plasma, 33 µL 
500 mM CaCl2, and 4 µL 1 U/µL thrombin, suspended on silk suture in sterile saline, and 
washed ten times over 24 hours to remove excess fibrinogen and FPA. Plasma then was 
incubated at 37° C for one hour with selected quantities of inhibitors in the presence of the 
fibrin clots and FPA generation by clot-bound thrombin was quantified in the plasma as 
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above. The clots were subsequently imaged on a Varian 11.7T magnetic resonance 
system to quantify the surface area presented by each. The clots were imaged in 
transverse slices with a T2-weighted spin echo multislice sequence (2.5 s TR, 150 ms TE, 
4 signal averages, 128 phase encoding steps, 128 frequency encoding steps, 
12mmX12mmX19.2mm field of view, 16 1.2 mm thick slices). To determine surface area, 
images were processed and analyzed with custom scripts developed for Matlab.  
Inhibition of Human Plasma Clot Growth In Vitro 
Further testing of inhibition of bound thrombin was accomplished by evaluating clots 
suspended on silk suture prepared as above. 50 µL saline (n=3), bivalirudin (40 mg/mL) 
(n=3), bivalirudin NPs (n=3), PPACK (12.5 mg/mL) (n=3), or PPACK NPs (n=3) were 
added to 2 mL sterile saline surrounding the clots. The clots were incubated with inhibiting 
agents for 1 hour at 37° C, and then washed three times with sterile saline. The washed 
clots were immediately imaged with 1H MRI at 11.7T as above (1.7s TR, 100 ms TE, one 
signal acquisition, 128 phase encoding steps, 256 frequency encoding steps, 
127mmX127mmX16mm field of view, 16 1 mm thick slices). Citrated human plasma with 
500 mM CaCl2 was introduced in lieu of saline to surround the clots. The clots were 
imaged with the same sequence repeatedly for one hour following introduction of plasma. 
Magnetic resonance images of the clots were manually analyzed in NIH ImageJ to 
determine changes in clot volume after addition of plasma. 
Induction and Inhibition of Acute Thrombosis In Vivo 
All animal experiments were approved by the Washington University Animal Care and 
Use Committee and are based on National Institute of Health laboratory standards. The in 
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vivo effects of bivalirudin and bivalirudin NPs were determined in mice through application 
of the rose bengal thrombosis model to the common carotid artery as described 
previously15,17.10-12 week old male C57BL/6 mice (weight 25-30 g) were anesthetized 
with sodium pentobarbital prior to surgical isolation of the right common carotid artery. An 
ultrasonic Doppler flow probe (Transonic Systems, Ithaca, NY) was applied to the artery to 
measure relative flow rate in the isolated segment of the carotid for the duration of each 
experiment. A 1.5 mW 540 nm HeNe laser (Melles Griot, Carlsbad, CA) was focused on 
the artery. Bivalirudin NPs (n=6), or free bivalirudin (n=6) were injected as an IV bolus ten 
minutes prior to inducing thrombotic occlusion of the carotid by injecting rose bengal dye 
as an IV bolus (50 mg/kg; Fisher Scientific, Fair Lawn, NJ). Occlusion of the carotid artery 
was noted and experiments were terminated upon the stable (>5 minutes) maintenance of 
zero flow as measured by the flow probe. 
Following the rose bengal experiments, the common carotid arteries were excised, 
rinsed with saline, and preserved in 10% buffered formalin for three days prior to 
histological analysis with Carstair’s multichromatic staining method. After processing 
through alcohols and xylenes, the arteries were embedded in paraffin and sectioned at 5-
micron thickness. Hydrated sections were treated with 5% ferric alum, Mayer’s 
hematoxylin, picric acid-orange G solution, poncean-fuchsin solution, 1% phosphotungstic 
acid, and aniline blue to stain for fibrin, platelets, collagen, muscle, and red blood cells. 
Images of stained sections were analyzed via color deconvolution in NIH ImageJ. 
Bleeding times, activated partial thromboplastin time (APTT), or prothrombin time (PT) 
were determined in mice at 10, 20, 50, and 100 minutes after injection of bivalirudin NPs 
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as an IV bolus (n=3 at each time point). For measurement of bleeding times, the tail was 
transected 0.5 cm from the tip and submerged in warm water. Bleeding time was 
determined at the cessation of spontaneous flow of blood into the water. For determination 
of APTT or PT, blood was drawn from the left ventricle into citrate. 80 µL plasma was 
combined with 80 µL APTT or PT reagent (Beckman-Coulter) for 3 minutes prior to 
activation with 80 µL calcium chloride (.025 mol/L) followed by determination of 
coagulation time with a fibrometer.  
Statistics 
 Significance levels were determined by two-tailed two-sample unequal variance T-
tests. Error bars denoted standard error. Data fitting employed an iterative least-squares 
algorithm. 
 
3.3   Results 
Formulation of Bivalirudin-Functionalized PFC Nanoparticles 
Carbodiimide coupling enabled the addition of bivalirudin at its N-terminus to 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000 in 
particles prepared as described in the methods (Fig. 1). Prior to addition of bivalirudin, the 
NPs had a mean diameter as measured by dynamic light scattering of 174.2 ± 2.4 nm. 
After addition of bivalirudin and dialysis to remove uncoupled bivalirudin and excess 
carbodiimide, the particle diameter was determined as 174.7 ± 1.9 nm. While the particle 
size was unchanged by bivalirudin addition, the zeta potential shifted following coupling, 
from -39.64 ± 2.85 mV to -18.66 ± 6.22 mV (Fig. 2). The shift in zeta potential was 
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Figure 3.1 Schematic of the bivalirudin PFC-core NP. 99 mol% of the lipid film stabilizing 
the PFC core was L-α-phosphatidylethanolamine and 1% was 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (indicated by PEG spacers). 
After synthesis of the NPs, bivalirudin was coupled at its N-terminus to the PEG spacers.  
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Figure 3.2 Hydrodynamic diameter of NPs was measured before and after addition of 
bivalirudin to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene 
glycol)-2000] on the particle surface. Before conjugation, the particle diameter was 174.2 ± 
2.4 nm. After conjugation, the particle size was measured as 174.7 ± 1.9 nm. The zeta 
potential shifted from -39.64 ± 2.85 mV to -18.66 ± 6.22 mV after addition of bivalirudin, 
indicating a change in the surface chemistry of the NPs.  
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indicative of a change in the chemical composition of the particle surface with the 
replacement of carboxyl termini in 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethylene glycol)-2000 with bivalirudin. 
The alteration to the particle surface and the covalent linking of bivalirudin to the lipid 
surface was further explored through fluorescence quantification assay. Bivalirudin not 
bound to the surface of the NPs after the coupling procedure but before dialysis was 
extracted from the emulsion through Cleanascite centrifugation. Uncoupled bivalirudin was 
quantified by tyrosine fluorescence and compared to the quantity of bivalirudin added in 
excess during carbodiimide coupling to determine that approximately 24000 bivalirudin 
were coupled to each particle (Fig. 3). 
Bivalirudin Nanoparticles Efficiently Inhibit Thrombin in Solution 
Chromozym TH assay was used to define the activity of thrombin in the presence of 
various concentrations of free bivalirudin or bivalirudin NPs. Thrombin digestion of the 
Chromozym substrate was observed to occur at a linear rate after one-minute incubation 
of thrombin with bivalirudin or bivalirudin NPs, indicating that the inhibition reaction had 
reached equilibrium. The model of Stone and Hofsteenge16, applicable to tight binding 
reversible inhibitors of serine proteases, was employed to measure the rate of cleavage of 
the substrate by thrombin after allowing the inhibition reaction to reach equilibrium. 
According to equation 2, the steady-state rate of substrate digestion vs was delineated as 
a function of the thrombin concentration Et of 12 nmol/L, the variable concentration of the 
inhibitor It, and the effective inhibition equilibrium constant KI’. Iterative fits of vs for 
equation 2 with constant Et and variable It provided values of KI’ for bivalirudin and 
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Figure 3.3 Tyrosine fluorescence was used to quantify bivalirudin. A standard linear 
relationship was determined between the magnitude of fluorescence at 274 nm and 
concentration of bivalirudin (black line/data points). After coupling bivalirudin to precursor 
particles (but before dialysis), centrifugation and lipid resorption permitted separation of 
particles from uncoupled bivalirudin. Bivalirudin in the supernatant (purple data point) was 
quantified using the obtained standard curve. Noting that the quantity of bivalirudin added 
to each particle was equal to the amount included in coupling minus the amount available 
at the end of coupling, it was determined that ~24,000 bivalirudin were coupled to each 
particle.  
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bivalirudin NPs.  
For free bivalirudin in solution, a KI’ of 121.18 nmol/L was extrapolated. Bivalirudin on 
NPs exhibited a KI’ of 209.31 nmol/L, illustrating minimal diminution of molecular bivalirudin 
activity against thrombin when sterically restricted to the particle surface. In contrast, 
PPACK, used previously as the functional moiety on the first antithrombotic NP, exhibited 
a KI’ of 12.077 nmol/L according to the tight-binding inhibitor model (Fig. 4). Notably, 
although the individual bivalirudin molecules on the particle surface exhibited a small 
diminution of activity, the particle, considered as an inhibiting entity itself, exhibited a much 
higher affinity for thrombin. Setting It to represent the concentration of bivalirudin NPs in 
equation 2 for the data in Figure 4, a KI’ of 2.1741 fmol/L was derived from iterative least 
squares fitting (not shown). Kinetic modeling specific to the properties of multivalent 
inhibitor such as the bivalirudin nanoparticle is explored in Appendix 2. A multivalent 
kinetic model is applied therein to data indicative of bivalirudin nanoparticle binding to 
surface-bound thrombin. 
Bivalirudin Nanoparticles Inhibit Clot-Bound Thrombin  
Fibrinopeptide A (FPA) ELISA experiments further elucidated the versatile and potent 
means by which bivalirudin NPs inhibit thrombin in active clotting processes. The work of 
Weitz et al. used the FPA ELISA to show that bivalirudin and PPACK equally inhibit fibrin 
generation by thrombin in solution or thrombin bound in clots13. Analogous assays 
demonstrated here that bivalirudin NPs or PPACK NPs also successfully prevented fibrin 
formation by soluble and fibrin-bound thrombin. 
Human alpha thrombin in the fluid phase generated FPA in citrated plasma in a  
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Figure 3.4 Thrombin cleavage of Chromozym TH indicated thrombin activity after 
incubation with various inhibitors. Increasing concentrations of bivalirudin NPs (purple), 
free bivalirudin (black), or PPACK (red) diminished thrombin activity. The relationship 
between inhibitor concentrations and thrombin activity was described with a model for 
tight-binding reversible inhibition of serine proteases. Considering the molar equivalent of 
bivalirudin presented by functionalized NPs, the kinetics of bivalirudin on the NPs were 
determined identically, registering a KI' of 209.31 nM (purple). The model determined a KI' 
of 121.18 nM for free bivalirudin (black). The small diminution in activity of individual 
bivalirudin on particles is compensated by the presentation of ~24000 bivalirudin by each 
particle. For comparison, PPACK, a previously studied irreversible covalent inhibitor, was 
evaluated with an identical model to have a KI' of 12.08 nM (red). 
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concentration-dependent manner. The addition of bivalirudin, bivalirudin NPs, PPACK, or 
PPACK NPs to plasma over a range of concentrations resulted in concentration-
dependent inhibition of the generation of FPA by thrombin (Fig. 5a, 6a, 7a, 8a). For 
bivalirudin, conjugation to the NP only minimally effected its inhibition of FPA release. 
Similar results were observed with PPACK, where the inhibitor on the particle exhibited 
concentration-dependent activity that was slightly reduced relative to the free inhibitor. As 
with the inhibition of Chromozym TH digestion, this small reduction in bivalirudin effect is 
overwhelmed by considering that the NP, to each of which approximately 24,000 
bivalirudin are permanently bound, is an inhibiting entity itself present in much lower 
concentration than the bivalirudin.  
Further FPA ELISAs were employed to examine FPA release by active thrombin bound 
in fibrin clots. Weitz et al. previously determined that bound thrombin is responsible for 
FPA release from fibrin clots incubated in plasma and that the quantity of FPA release is 
directly proportional to the clot surface area13. For normalization, the surface area of each 
clot used in this study was measured by MRI (Fig. 9). After incubation of the clots with 
citrated human plasma or plasma containing set concentrations of PPACK, bivalirudin, 
PPACK NPs, or bivalirudin NPs, FPA concentration in the plasma was determined, 
normalized to clot surface area, and compared to FPA release into plasma not containing 
inhibitors. The extent of thrombin inhibition was measured and compared to the extent of 
inhibition of fluid phase thrombin by equivalent concentrations of inhibitors. For each 
inhibitor, the extent of bound thrombin inhibition was within or above error observed in the 
inhibition of fluid-phase thrombin (Fig. 5b, 6b, 7b, 8b). 
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Figure 3.5 Fibrinopeptide A (FPA) ELISA determined the quantity of FPA released by 
thrombin cleavage of fibrinogen. Quantity of FPA release in plasma was dependent on the 
concentration of thrombin or bivalirudin (a). Inhibition of FPA release and thus thrombin 
was 42.31%, 60.10%, and 82.13% complete for 5, 10, and 20 µM bivalirudin (BVR). 
Thrombin bound in fibrin clots also generated FPA when clots were incubated in plasma. 
Addition of bivalirudin to the plasma diminished the generation of FPA by clots. Inhibition 
of FPA release elicited by bound thrombin was 46.45%, 65.18%, and 76.95% complete for 
5, 10, and 20 µM bivalirudin (BVR) (b).  
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Figure 3.6 Fibrinopeptide A (FPA) ELISA determined the quantity of FPA released by 
thrombin cleavage of fibrinogen. Quantity of FPA release in plasma was dependent on the 
concentration of thrombin or bivalirudin NPs (a). Inhibition of FPA release and thus 
thrombin was 29.15%, 47.81%, and 69.60% complete for 5, 10, and 20 µM bivalirudin 
(BVR) on NPs. Thrombin bound in fibrin clots also generated FPA when clots were 
incubated in plasma. Addition of NPs to the plasma diminished the generation of FPA by 
clots. Inhibition of FPA release elicited by bound thrombin was 24.06%, 51.66%, and 
72.33% complete for 5, 10, and 20 µM bivalirudin (BVR) on NPs (b). The results indicate 
that bivalirudin NPs perform equally well against bound and free thrombin. 
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Figure 3.7 Quantity of FPA release in plasma was dependent on the concentration of 
thrombin or PPACK (a). Inhibition of FPA release and thus thrombin in the fluid phase was 
49.24%, 66.53%, and 85.82% complete for 5, 10, and 30 nM PPACK. Inhibition of FPA 
release elicited by bound thrombin was 44.50%, 64.06%, and 83.26% complete for 5, 10, 
and 30 nM PPACK (b). The results confirm that PPACK performs equally well against 
bound and free thrombin. 
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Figure 3.8 Quantity of FPA release in plasma was dependent on the concentration of 
thrombin or PPACK (a). Inhibition of FPA release and thus thrombin in the fluid phase was 
6.30%, 14.84%, and 34.55% complete for 5, 10, and 30 nM PPACK on NPs. Inhibition of 
FPA release elicited by bound thrombin was 20.03%, 31.59%, and 49.76% complete for 5, 
10, and 30 nM PPACK on NPs (b). The results indicate that PPACK NPs perform equally 
well against bound and free thrombin. 
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Figure 3.9  Human plasma clots were formed on suture with cylindrical templates and 
imaged in transverse slices at 11.7T with a T2-weighted spin echo sequence (a). Outlines 
drawn in Matlab were used to determine the circumference of each imaged clot cross-
section, leading to a calculation of clot surface area (b). 
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Bivalirudin Nanoparticles Inhibit Human Plasma Clot Growth In Vitro 
After submersion of fibrin clots in plasma, sequential MRIs allowed measurement of 
changing clot volume. Additional clotting was observed in T2-weighted spin echo MRIs as 
dark formations extending from the original clot surfaces (Fig. 10b). Clot boundaries were 
drawn at the edge of the new growth in each slice of multislice images, allowing clots to be 
reconstructed in three dimensional images (Fig. 10b, 10c). Demarking the new clot 
volume as the sum of the volumes of the initial clot and the new growth, clot volume could 
be determined as a function of time after addition of new plasma. Accumulation of clot 
volume was observed for clots treated with saline, PPACK, or bivalirudin (Fig. 10d). At one 
hour after introduction of plasma clots treated with saline, PPACK, or bivalirudin, clots had 
grown to 381.17% ± 43.48%, 355.70% ± 44.72%, or 314.33% ± 14.29% initial volume, 
respectively. For clots treated with PPACK NPs or bivalirudin NPs, binding of NPs on the 
clot surface was observable via 19F MRI (Fig. 10a). Clots with a protective layer of 
thrombin inhibiting NPs (either PPACK or bivalirudin) did not grow when exposed to 
plasma (Fig. 10c, 10d, 10e). Whereas clots without nanoparticle treatment grew 
sigmoidally to nearly fill the volume of vessel containing the plasma, clots treated with 
PPACK NPs or bivalirudin NPs did show significant change in volume over one hour (Fig. 
10d, 10e).  
Induction and Inhibition of Acute Thrombosis In Vivo 
As described in the methods, diminishing blood flow in the laser-injured carotid was 
monitored with a Doppler flow probe (Figure 11). The progression to zero flow occurred at 
different times for different treatment groups. In accordance with standard analysis of the  
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Figure 3.10 Human fibrin clots treated with saline, PPACK, bivalirudin, PPACK NPs, or 
bivalirudin NPs were submerged in human plasma. Via MRI, 19F magnetic resonance 
signal from the core of NPs was observed on the surface of clots treated with PPACK NPs 
or bivalirudin NPs (a). After exposure to plasma, additional clotting developed on the 
surface of clots treated with saline, PPACK, or bivalirudin. The clot growth was observed in 
1H MRI of the clots and marked manually for three dimensional reconstruction images of 
clots (b). No growth was observed in images of clots treated with PPACK NPs or 
bivalirudin NPs (c). Growth of clot volume, as determined by MRI, was measured over one 
hour. Representative growth curves are shown in (d). At one hour, clots treated with 
saline, PPACK, or bivalirudin had significantly grown and clots treated with PPACK NPs or 
bivalirudin NPs had not (e).  
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Figure 3.11 Representative carotid blood flow time courses are depicted for mice 
subjected to Rose Bengal injury of the carotid after treatment with PPACK (red), bivalirudin 
(grey), PPACK-NPs (blue), or bivalirudin NPs (purple). PPACK-NPs and bivalirudin NPs 
delayed the development of an occlusive thrombus. Free PPACK and bivalirudin time 
courses were indistinguishable from control time courses (not shown).  
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rose bengal model, the time to stable occlusion of the carotid delineated the treatment 
effect for each group17. Effective antithrombotics are known to delay the onset of carotid 
occlusion. In previous work, PPACK NPs extended thrombotic occlusion time to 145 ± 13 
minutes, as compared to a control time of 70 ± 17 minutes8. At a single dose of 10 mg/kg 
free bivalirudin administered 10 minutes prior to induction of injury, the average occlusion 
time was 83 ± 13 minutes, indicating no significant difference between the saline sham 
and the bivalirudin treatment as administered. The bivalirudin emulsion, administered at a 
dose of 1 ml/kg bolus (presenting an equivalent dose of 6.24 mg/kg bivalirudin), delayed 
the occlusion of the injured carotid to 111 ± 14 minutes (Figure 12a). As compared with 
the free bivalirudin, the bivalirudin emulsion significantly extended the stable carotid 
occlusion time over the control value. In previous work, we have reported that the effect of 
the emulsion is specific to its functionality by showing that NPs containing 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000 without a 
conjugated inhibitor do not extend the time to occlusion (Fig. 13)8.    
Bleeding times, activated partial thromboplastin time (APTT), and prothrombin time 
(PT) were measured after administration of bivalirudin NPs (Fig. 12b, 14). For all tests, a 
time course for the blood pool effect of bivalirudin NPs indicated that the particles exerted 
a rapidly diminishing systemic anticoagulant effect in the blood pool. Bleeding times were 
protracted at 10 and 20 minutes after administration of particles, but were indistinguishable 
from control values at 50 or 100 minutes. Blood samples taken 10 minutes after bivalirudin 
NP bolus demonstrated extension of APTT and PT over control times, but samples taken 
at 20 minutes or later manifested no significant effect on coagulation parameters. Thus the  
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Figure 3.12 Time to stable occlusion of the carotid after rose bengal photochemical injury 
was measured in mice treated with various antithrombotics. Saline sham resulted in 
occlusion time of 70 ± 17 minutes. Bivalirudin bolus (n=4) did not significantly extend time 
to occlusion. Bivalirudin NP treatment (n=5) did significantly extend occlusion time over the 
control time. Treatment with PPACK NPs was previously shown to more than double 
occlusion time relative to the control value (a). In the blood pool, bivalirudin NPs delayed 
the bleeding time at 10 and 20 minutes after administration and the PT at 10 minutes after 
administration, but did not exert a significant effect thereafter (b).  
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Figure 3.13 Data from Figure 4 is compared to previously obtained values for time to 
stable carotid occlusion. Free PPACK (n=7) or control NPs not carrying a thrombin 
inhibitor (n=7) had no effect on time to stable occlusion of the carotid in laser-injured mice. 
Heparin (n=4) extended the occlusion time to 102 ± 13 minutes.  
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Figure 3.14 In blood draws, bivalirudin NPs delayed the APPT at 10 minutes after 
administration, but did not exert a significant effect at 20, 50, or 100 minutes after 
administration (b).  
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bivalirudin NPs inhibited occlusion at the site of arterial injury over a prolonged interval, yet 
fortuitously exhibited a short-lived systemic effect. 
Following fixation in formalin, occluded mouse arteries were prepared for Carstair’s 
staining. The clots in the arteries exhibited a distribution of platelets (stained blue) in a 
fibrin matrix (stained pink) (Fig. 15). Comparing clots formed in the presence of control 
NPs (embedded in paraffin from previous work) to clots formed in the presence of 
bivalirudin NPs, denser and more abundant clusters of platelets were evident in control 
clots. Color deconvolution and analytical tools in ImageJ were used to evaluate the area of 
each clot section occupied by platelet staining. Clots formed in the presence of control 
NPs exhibited platelet staining in 41.31% ± 4.09% of the cross-sectional area, as opposed 
to 27.65% ± 2.26% of the cross-sectional area in clots formed in the presence of 
bivalirudin NPs (Fig. 16).  
 
3.4   Discussion 
Antithrombotic NPs combine the thrombin-targeting capacity of direct inhibitors10,11 and 
the well-characterized in vivo behavior of stable perfluorocarbon emulsions18 to provide a 
material with potent action against acute thrombosis and minimal systemic effects8. In this 
chapter, an antithrombotic nanostructure functionalized with the peptide bivalirudin 
optimized this construct to restore a local anticlotting surface. The new particle largely 
mitigates the problem of nonspecificity of PPACK while retaining features of sustained 
local antithrombin activity and rapid diminution of residual systemic anticlotting action (see 
Appendix 1). While PPACK used in the prototype thrombin-inhibiting NP acts irreversibly  
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Figure 3.15 Clots formed after bivalirudin NP treatment (BVR NPs) or control NP 
treatment (Control NPs) were evaluated via Carstair’s stain. In the presence of bivalirudin 
NPs as compared to control NPs, clots exhibited less platelet staining (blue) than fibrin 
staining (pink). With control NP treatment, staining of platelets was more prominent. 
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Figure 3.16 Area occupied by platelet staining within cross-sections of thrombi was 
evaluated in NIH ImageJ. For cross-sections of arteries treated with control NPs, platelet 
staining occupied 41.31% ± 4.09% of thrombus area. For arteries treated with bivalirudin 
NPs, platelet staining occupied 27.65% ± 2.26% of thrombus area. 
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only on the catalytic site of thrombin, bivalirudin binds reversibly to the catalytic site and to 
thrombin exosite I, resulting in much greater specificity for thrombin12. Bivalirudin also 
exhibits undiminished activity against fibrin-bound thrombin and even manifests a capacity 
for displacement of thrombin from polymerized fibrin13,19. The use of a NP carrier to form 
an anticlotting surface enhances bivalirudin’s potency by presenting more than 20,000 
active molecules per particle to enhance local thrombin surveillance. The synergistic 
activity against platelets through inhibition of thrombin’s action toward protease activated 
receptors (PARs)20, which is a principal activation pathway, confers additional local 
anticoagulant efficacy.  
Given the problems plaguing interventional and diagnostic strategies for treatment of 
acute thrombosis, antithrombotic NPs may be ideally suited for use in acute vascular 
syndromes. NPs outperform heparin in inhibiting occlusive thrombus formation in a mouse 
model8, but induce only a short-lived extension of APTT and PT in the blood pool and rapid 
normalization of bleeding times. Whereas most anticoagulants currently in clinical use 
increase bleeding times1,21, this prototypical antithrombotic NP exhibits an anticoagulant 
effect that is exclusive to the site of acute injury after a short systemic phase. The rapid 
blood distribution phase (~10 minutes), together with an elimination half-life of ~3 hours, 
essentially reduces the circulating concentration of antithrombotic NPs to a level that no 
longer exerts anticoagulant activity systemically after 20-50 minutes (see Appendix 1). 
Accordingly, the availability of agents that could rapidly reverse the systemic anticoagulant 
effects is not required as bleeding times are rapidly normalized. Nevertheless, the 
hypothesized selective buildup of particles at the intended site would achieve a sustained 
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thrombin surveillance effect lasting hours. Those NPs that do not bind to the intended site 
would simply be cleared rapidly by the liver and disposed of silently and without toxic side 
effects18. 
For potential clinical evaluation, dosing requirements will have to be determined, but it 
is evident, through FPA experiments and in vitro exploration of clot growth, that the 
biological effect of antithrombotic nanoparticles at the site of thrombosis exceeds the blood 
pool activity as a consequence of focal accumulation of the targeted material around sites 
of active prothrombin conversion to thrombin. Due to necessity of intravenous 
administration, the practical utility of the examined agents would be focused to acute use, 
where a number of important indications exist for emergent application such as acute 
vascular syndromes, angioplasty3, microangiopathy22, acute kidney injury23, and 
arteriovenous fistula and/or graft maintenance24. This chapter demonstrates the versatility 
of the PFC NP platform as a means of providing acute antithrombotic care with highly 
targeted therapeutic effects and modifiable functional components.  
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Chapter 4 
 
Thrombin-Targeted Nanoparticles Manifest Magnetic Resonance Imaging Contrast 
Specific to Sites of Acute Prothrombotic Arterial Injury 
 
4.1   Introduction 
 Given results in chapters 2 and 3 indicative of thrombin-inhibiting nanoparticle activity 
specific to arterial injury, it was hypothesized that PPACK and bivalirudin nanoparticles 
specifically bind to sites of acute thrombosis. This site-specific activity would be 
observable via 19F magnetic resonance spectroscopy and imaging. As evident in the 
development of thrombin-targeted particles and in previous work, perfluorocarbon (PFC) 
nanoparticles can be modified chemically to achieve targeted drug delivery because 
nanoparticles can carry large payloads of therapeutic agents1-3. Fortuitously, PFC 
nanoparticles also generate a prominent 19F signal for MRI/MRS that is unique in the 
proton-dominated background of typical MR imaging.  It has been shown that the intensity 
of the 19F MRI/MRS signal is linearly correlated with the concentration of PFC 
nanoparticles in a region of interest3-5. Thus, 19F MRI and MRS are capable of registering 
the location and quantity of functionalized PFC nanoparticles in the biological milieu3-7.  
Beyond definitively showing that thrombin-targeted nanoparticles specifically bind to 
sites of acute thrombosis, the determination of thrombosis imaging contrast for thrombin-
targeted nanoparticles carries substantial diagnostic significance. Stuttering thrombosis 
and microembolization can affect the assessment of outcomes with current thrombosis 
treatment strategies8. The thrombin-inhibiting nanoparticle may offer an approach for 
detecting acute thrombosis via 19F MRI. This diagnostic capacity could guide more 
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thorough interventions in thrombotic patients, capturing multiple thrombi, including those in 
microvasculature that would otherwise go undetected. 
The work presented herein used MRI and MRS to examine thrombi induced in mouse 
arteries, formed during the work described in chapters 2 and 3. Additional work evaluated 
the progress of forming rabbit femoral artery thrombi as part of a multimodal imaging 
study. The quantity of retained nanoparticles was evaluated, indicating that thrombin-
targeted nanoparticles specifically bind at sites of thrombotic arterial injury to a greater 
degree than non-functionalized nanoparticles. The results presented suggest that PPACK 
or bivalirudin particles can be detected specifically and quantitatively as they accumulate 
at sites of activated thrombin with the use of magnetic resonance imaging and 
spectroscopy of the fluorine (19F) particle core.  In this manner, acute thrombosis was 
identified by molecular targeting of thrombin, which concomitantly results in its inhibition.  
 
4.2   Methods 
Left (unaffected) and right (injured) arteries from six mice evaluated in chapter 2 were 
reserved for analysis via magnetic resonance imaging and spectroscopy. Three of these 
mice received PPACK nanoparticles and three received blank nanoparticles prior to 
induction of thrombosis. Arteries were excised and rinsed with saline to remove retained 
blood prior to submersion in fixative as described previously. Imaging and spectroscopy 
was conducted with a custom-built single-turn solenoid coil on a Varian 11.7T MR system. 
19F signal from nanoparticles in the artery and from a perfluorooctylbromide standard was 
assessed via spin echo spectroscopy (3 s pulse repetition time (TR), 2 ms echo time (TE), 
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256 signal averages (NT), 13.25 minute acquisition time). 19F spin echo images (1.3 s TR, 
12 ms TE, 512 NT, 32 phase encoding steps, 64 frequency encoding steps, 
9mmx6mmx1mm field of view) were obtained to depict nanoparticle binding in the excised 
artery. 1H spin echo images (1.5 s TR, 20 ms TE, 4 signal averages, 128 phase encoding 
steps, 256 frequency encoding steps, 9mmx6mmx1mm field of view, 5 .2mm slices) 
allowed coregistration of the fluorine images with an anatomical image of the artery.  
Similarly, following the rose bengal experiments in chapter 3, the common carotid 
arteries from mice treated with bivalirudin NPs were excised, rinsed with saline, and 
preserved in 10% buffered formalin. Imaging and spectroscopy was conducted with a 
custom-built single-turn solenoid coil on a Varian 11.7T MR system. 19F spectra capturing 
signal from the artery and from a perfluorooctylbromide standard were obtained by non-
localized spin echo spectroscopy (3 s pulse repetition time (TR), 2 ms echo time (TE), 256 
signal averages, 12.88 minute acquisition time). 19F spin echo images (1.1 s TR, 12 ms 
TE, 512 signal averages, 32 phase encoding steps, 64 frequency encoding steps, 
5mmX5mmX1cm field of view) were obtained to depict NP binding in the excised artery. 1H 
spin echo images (2 s TR, 14 ms TE, 4 signal averages, 128 phase encoding steps, 256 
frequency encoding steps, 5mmx5mmx1mm field of view, 11 slices) allowed coregistration 
of the fluorine images with an anatomical (proton) image of the artery. 
PPACK NPs were implemented in rabbits to explore the use of thrombin-inhibiting PFC 
NPs as thrombosis imaging contrast agents in a larger animal model with clinically relevant 
multimodal imaging techniques. 12 month cholesterol-fed rabbits were anesthetized via 
ketamine/xylazine (120 mg/24 mg IM bolus followed by infusion of ketamine and periodic 
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IM bolus of xylazine and acepromazine) in accordance with observed pulse, respiration 
rate, blood oxygenation, and body temperature. The femoral artery was exposed and 
illuminated by 1.5-mW 540-nm HeNe laser (Melles Griot, Carlsbad, CA, USA) and 50 
mg/kg Rose Bengal was administered as an IV bolus. Laser exposure of the artery was 
maintained for 3.5 hours while monitoring flow distal to the site of injury via Doppler probe 
(Transonic Systems, Ithaca, NY, USA). Ultrasound images (Doppler and echo) acquired 
with a Philips IE33 system every 30 minutes after induction of injury provided a 2 cm by 2 
cm longitudinal view of the femoral artery at the site of injury during formation of the arterial 
thrombus. 
At 200 minutes after induction of injury, the site of injury was sutured and the rabbit 
was subsequently monitored via magnetic resonance angiography on a 3T Philips Achieva 
MR system to demonstrate non-invasive detection of the injury. PPACK NPs were 
administered as a 1 ml/kg IV bolus at the beginning of MRI to accumulate at the site of the 
formed thrombus. Conventional time-of-flight MR angiography, phase-contrast 
angiography, and dark blood T1-weighted imaging were focused on the injured femoral 
artery to detect the injury with multiple imaging techniques.  
Magnetic resonance imaging at 3T employed a custom-built open birdcage coil 
compatible with Philips’ proprietary connectors. Dark blood T1-weighted imaging was 
accomplished with a fast spin echo sequence with four echoes per repetition and inversion 
recovery fat suppression (380 ms TR, 11 ms TE, 8 signal averages, 208 phase encoding 
steps, 208 frequency encoding steps, 128mmx128mmx4mm field of view, 19 slices). Time-
of-flight angiography entailed a gradient echo sequence with 60-degree flip angle and 
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Shimadzu motion artifact reduction technique (Minimal TR of 13 ms and TE of 4 ms as 
permitted by Philips software, 2 signal averages, 160 phase encoding steps, 160 
frequency encoding steps, 160mmx160mmx2mm field of view, 80 slices). Phase contrast 
angiography was achieved with a gradient echo sequence with 15-degree flip angle and 
phase contrast velocity of 20 cm/s (Minimal TR of 13 ms and TE of 4.9 ms as permitted by 
Philips software, 2 signal averages, 160 phase encoding steps, 160 frequency encoding 
steps, 200mmx200mmx0.5mm field of view, 70 slices). Angiography reconstructions were 
synthesized in Philips software with the use of maximum intensity projections. 
After sacrifice, the affected femoral artery was removed and preserved in formalin for 
ex vivo imaging on an 11.7T Varian MR system. 19F spin echo MRI (1.3 s TR, 13.3 ms TE, 
512 signal averages, 32 phase encoding steps, 64 frequency encoding steps, 
1.39mmX1.15mmX1.2mm field of view, 14 slices) identified the retention of NPs in the 
injured artery. 1H spin echo MRI (1.5 s TR, 17 ms TE, 4 signal averages, 128 phase 
encoding steps, 256 frequency encoding steps, 1.39cmX1.15cmX1.2mm field of view, 14 
slices) provided anatomical images for co-registration with 19F MRI. Magnetic resonance 
images of excised rabbit arteries were opened and analyzed in Matlab. A Matlab script 
permitted reconstruction of a three-dimensional image of the preserved artery with a 
superimposed 19F image of nanoparticles retained at the site of arterial injury. 
 
4.3   Results 
19F magnetic resonance imaging and spectroscopy were used to assess Perfluoro 15-
Crown-5 Ether (CE) NMR signal present in selected arteries due to retention of PFC 
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nanoparticles. Figure 1a depicts an excised occluded artery from a mouse treated with 
PPACK nanoparticles. In the left panel, a proton MRI illustrates a .2 mm cross-section of 
the artery with a dense clot in the center. A false color 19F 1 mm projection image in the 
right panel depicts nanoparticle content in the artery. An overlay of the two images 
indicated strong colocalization of the particles with the clot, implying the possibility of 
tracking PPACK nanoparticles as they act to interrupt clot formation. 
 Quantitative 19F spectroscopy was employed to determine the extent of nanoparticle 
incorporation into clots from six mice (Fig. 1b). In mice treated with PPACK nanoparticles, 
injured arteries retained .31 ± .14 fmol and unaffected arteries retained .04 ± .01 fmol 
nanoparticles. In mice treated with control nanoparticles, injured arteries retained .07 ± .03 
fmol and uninjured arteries retained .03 ± .02 fmol.  
The perfluorocarbon in the bivalirudin nanoemulsion also generated a signal detectable 
by magnetic resonance (MR) imaging and spectroscopy. The retention of bivalirudin NPs 
in injured arteries was visualized with 19F MRI (Fig. 2a). The excised arteries were imaged 
with a proton spin echo sequence in 1 mm slices. Subsequently, 19F images were captured 
to show the location of NPs relative to the artery. By overlaying a false color fluorine 
projection image on a proton image slice centered on the injured artery, the retention of 
particles in the injured artery was evident. Accordingly, the particles appeared to be 
sequestered in the clot formed in the injured carotid. Excised arteries obtained after 
administration of bivalirudin NPs contained NPs in MR-quantifiable amounts (Fig. 2b). Via 
quantitative MR spectroscopy, 0.34 ± .02 fmol of bivalirudin NPs were detected in carotids 
injured under treatment. In previous work, control NPs adhered in quantities of 0.07 ± 0.03  
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Figure 4.1 In mice receiving treatment with control nanoparticles (n=3) or PPACK 
nanoparticles (n=3), both carotid arteries were excised following induction of occlusive 
thrombi in the right carotid artery. 19F MRI at 11.7T exhibited coregistration of 19F signal 
from PPACK nanoparticles with 1H images depicting the occlusive clot in the artery (a). 19F 
MRS was used to quantify retention of nanoparticles in the injured right carotid artery (RA) 
and the unharmed left carotid artery (LA). Retained particles ± standard error are 
represented in (b).    
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Figure 4.2 Imaging of arteries containing occlusive clots. In mice receiving treatment with 
control NPs (n=3) or bivalirudin NPs (n=5), the carotid artery was excised following injury. 
19F MRI at 11.7T showed 19F signal from bivalirudin NPs (scale bar represents fM 
concentration) and identified retention of the particles in injured arteries, as imaged with 1H 
MRI (a). 19F MRS was used to quantify retention of NPs in the arteries. 0.34 ± 0.02 fmol 
bivalirudin NPs or 0.07 ± 0.03 fmol control NPs were bound in the injured arteries (b). 
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fmol in injured arteries.  
Further exploration of thrombosis-specific binding and detection in larger animals with the 
use of the thrombin-inhibiting NPs was accomplished by applying PPACK NPs in a 
cholesterol-fed rabbit model. At 200 minutes after induction of femoral artery injury by 
introduction of Rose Bengal dye, a thrombotic mass was detectable by ultrasound echo 
images. A defect in laminar flow was evident at the site of the injury in ultrasonic Doppler 
flow imaging (Fig. 4b). PPACK NPs then were delivered IV and circulated for two hours. 
Proton imaging with 3T MRI at this time also revealed stable thrombus formation that was 
detectable by black blood, time-of-flight, and phase contrast angiography techniques (Fig. 
3). A subsequent high-resolution ex-vivo image of the injured artery and bound particles 
was obtained at 11.7T, revealing abundant targeted NPs at the site of injury coating the 
thrombus surface (Fig. 4c). 
 
4.4   Discussion 
The above data confirm the site-targeted accumulation of thrombin-inhibiting 
perfluorocarbon nanoparticles in acute clots. Thrombi in mice exhibited substantial and 
specific accumulation of both PPACK and bivalirudin nanoparticles. The particles bound to 
injured arterial segments in a manner not observed for contralateral healthy arteries or for 
non-targeted particles in injured arteries. Imaging data not only showed that PPACK and 
bivalirudin nanoparticles focus their accumulation, and thus inhibitory effects, on acute 
arterial injury sites, but also demonstrated in mouse and rabbit models the potential utility 
of thrombin-inhibitor nanoparticles for detecting and tracking the process of acute 
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Figure 4.3 Magnetic resonance angiography for detection of femoral artery injury in a 
cholesterol-fed rabbit at 3T. A defect in arterial flow was evident in 2D time of flight and 
dark blood imaging of the femoral. A maximum intensity projection image for phase-
contrast angiography revealed diminished flow in the injured segment of the artery. 
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Figure 4.4 In rose bengal injured cholesterol-fed rabbit femoral arteries, development of a 
thrombus was tracked over 200 minutes with Doppler flow ultrasound imaging (a,b). After 
formation of a thrombus, PPACK NPs were administered as a contrast agent to highlight 
the site of injury. After excision, the injured femoral artery was imaged at 12T. False color 
19F imaging identified the retention of NPs in a three dimensional image of the excised 
artery (color scale bar represents 0-150 nM concentration) (c). 
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thrombosis. 
Given the colocalization of the thrombin-targeted particles with sites of thrombosis and 
the extensive previous use of PFC particles to provide magnetic resonance, ultrasound, 
optical and SPECT contrast7,9-11, PPACK and bivalirudin nanoparticles exhibit promise as 
a tool for specific diagnostic mapping of acute thrombosis. As demonstrated previously for 
detection of fibrin in clots5,12, 19F signatures from PFC particles can be quantified in 
molarity to provide a gross estimate of their local concentration. As indicated by 19F data, 
the isolation of thrombin-targeted particles at a forming thrombus establishes a focal 
antithrombotic surface covering the prothrombotic nascent clot. The ability of the particles 
to cover the clotting surface with a thrombin-inhibiting coating could, as indicated in 
chapters 2 and 3, seal off further thrombus formation as PPACK or bivalirudin on the 
bound particles continues to inhibit newly activated thrombin. 
The perfluorocarbon-core NP is the first known thrombin inhibitor to provide magnetic 
resonance contrast specific to sites of acute thrombosis, because free thrombin generally 
is not detectable in serum as it is bound up rapidly by other proteins designed to remove it 
from the circulation. Alternative imaging agents have been described for fibrin12-14, but 
whether they might bind to and demonstrate newer versus older clots is not certain. 
Furthermore, fibrin is ubiquitous in many conditions of inflammation15, wound healing16, 
cancer metastasis17, and atherosclerosis18,19 so that its specificity for an acute vascular 
event can be problematic. Moreover, traditional treatments for thrombosis feature 
unpredictable and continued formation of multiple thrombi and microemboli that can go 
undetected8. The thrombin-inhibiting NP could provide imaging contrast that permits the 
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detection of otherwise unnoticed thrombotic events, providing a guide for further 
antithrombotic and thrombolytic intervention.  
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Chapter 5 
Conclusions 
There continues to be a medical need for new potent and highly specific antithrombotic 
agents with minimal toxicity for the treatment of thrombosis in acute coronary syndromes1-
3, stroke4, venous thrombosis2,5, and stent placement6,7. We suggest that the thrombin-
targeted particles developed here could be evaluated in acute vascular syndromes as 
potent local therapies with improved safety profiles serving as bridges to outpatient oral 
therapy. 
The onset of thrombosis in acute vascular syndromes coincides with disruption of a 
normally anticoagulant endothelial barrier either through plaque rupture or focal erosion 
that exposes an underlying hypercoagulable milieu to circulating clotting factors8-12. The 
conventional management of such events entails the use of combinations of systemic 
anticoagulants and antiplatelet agents that attenuate clotting ubiquitously until such time 
as these focal acute events “passivate” and an anticlotting surface is restored5.  
We have proposed an alternative approach to acute anticoagulant therapy with the use 
of perfluorocarbon nanoparticles (PFC NPs) functionalized with the direct thrombin 
inhibitors, D-Phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone (PPACK) or bivalirudin8. 
The binding of antithrombotic nanoparticles at the site of prothrombotic injury would 
establish a new anticlotting surface resistant to further thrombin activity. As represented 
schematically in Figure 1, the elimination of local thrombin activity by a NP anticoagulant 
surface is expected to mitigate further deposition of fibrin and platelets and provide long-
lived surveillance function against further clotting at a disrupted vascular site.  
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Figure 5.1 Schematic representation of clots without (a) and with (b) thrombin-inhibiting 
NPs. The figures are presented as hypothetical representations of a cross-section of a clot 
formed in a rabbit femoral artery, as imaged with MRI here as a single slice and in chapter 
4, Figure 4 in three dimensions. Each scheme depicts an injured segment of endothelium, 
with exposed fibrocollagenous tissue (orange) permitting the adhesion of activated 
platelets and strands of fibrin. Without NP treatment, active thrombin is abundantly bound 
in formed thrombi and is present in the blood (a). Platelets are being activated and 
immobilized by thrombin and by exposure to the active clotting surface. Formation of new 
fibrin strands is under way. With NP treatment, active thrombin in the blood and bound in 
clots is inhibited by adhered NPs (b). Formation of new fibrin and activation and deposition 
of platelets is forbidden by the NPs, both in a “passivating” layer at the site of arterial injury 
and in circulation.  
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In chapter 2, a first nanoparticle, featuring PPACK as its functional moiety, was 
synthesized and characterized. The PPACK nanoparticle inhibited thrombin in a manner 
consistent with the antithrombin activity of PPACK itself and the properties of the base 
nanoparticle, as explored further in Appendix 2. The PPACK nanoparticle successfully 
inhibited acute thrombosis while exhibiting short-lived effects on systemic clotting 
parameters.  
In chapter 3, a nanoparticle functionalized with bivalirudin was introduced and analyzed 
alongside the PPACK nanoparticle. The bivalirudin nanoparticle also successfully inhibited 
thrombin in solution and outperformed its component inhibitor in delaying occlusive 
thrombosis. The work of chapter 3 further shows through FPA ELISAs and imaging of in 
vitro clots that both bivalirudin and PPACK nanoparticles inhibit clot-bound thrombin. The 
nanoparticles appear unique in their ability to block the progress of thrombosis when 
bound to the surface of a clot.  
Finally, imaging data in chapter 4 serves two purposes, permitting insight into the 
behavior of nanoparticles while inhibiting thrombosis in vivo and indicating a capacity of 
thrombin-inhibiting nanoparticles to provide imaging contrast specific to thrombosis. The 
imaging data shows that thrombin-inhibiting nanoparticles, though they clear from the 
blood pool rapidly (see Appendix 1), adhere to sites of thrombosis over a course of 2-4 
hours. Additionally, the specificity of imaging contrast to thrombosis indicates that 
thrombin-inhibiting nanoparticles may be used as a diagnostic agent, in addition to its 
therapeutic capacity.  
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We have thus demonstrated activity of bivalirudin and PPACK NPs featuring immediate 
restitution of an anticlotting surface localized specifically to the site of injury. This work 
describes the design and initial implementation of thrombin-inhibiting nanoparticles 
capable of antithrombotic activity as described by Figure 1. The clinical implication is the 
opening of a new avenue in antithrombotic care, by which nanoparticles may be 
functionalized with suitable thrombin inhibitors to provide an anticoagulant layer over 
forming intravascular clots. This mode of preventing thrombosis represents a novel 
approach that could enable physicians to treat catastrophic thrombotic events with a single 
dose of anticoagulant that could permit MRI detection of thrombosis with a single dose of 
contrast agent. Furthermore the agent also treats the condition while eliminating the need 
for continuous infusions, thereby avoiding the risk of systemic anticoagulation and 
bleeding. 
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Chapter 6 
 
Appendix 1: MR-Based Pharmacokinetic Analysis of Perfluorocarbon Nanoparticles 
 
6.1   Introduction 
 
Traditional pharmacokinetic analysis requires multiple blood samples over extended 
time intervals to characterize the distribution and clearance of drugs and imaging agents in 
the bloodstream.  These blood samples must undergo chemical analysis later and 
subsequent data fitting to multi-compartmental models to define time constants and 
distribution volumes. Magnetic resonance spectroscopy (MRS) and magnetic resonance 
imaging (MRI) may be useful for real time analysis of pharmacokinetics of certain 
nanopharmaceuticals. MRI and MRS can offer an opportunity to follow the distribution and 
elimination of labeled therapeutic agents in real time without the need for multiple blood 
samples1-7. 
This data was obtained in an effort to employ 19F MRS for high resolution 
characterization of the pharmacokinetics of nanoparticles containing perfluoro-15-crown-5 
ether (crown ether) in the mouse after intravenous injection. We used the measured 19F 
signal magnitude from a selected vascular region in the mouse to derive the relative 
particle concentration in the blood as a surrogate for a blood draw measurement. After 
fitting the measured clearance of the particles to a biexponential model, we observed 
values for half-life in the blood that were comparable to those reported in previous work as 
delineated by blood sampling10,15 . We note that this spectroscopic method may substitute 
as a rapid real time analytical approach for defining pharmacokinetics of a nanoparticle 
with a unique blood signature. 
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6.2   Methods and Results 
PFC nanoparticles were prepared as described in previous work14. Briefly, the 
emulsions contained 20% (vol/vol) Perfluoro 15-Crown-5 Ether (Exfluor Research Corp.), 
2% (wt/vol) of a surfactant mixture, 1.7% (wt/vol) glycerin, and water for the balance. The 
surfactant, including 98 mole% egg yolk phosphotidylcholine (Avanti Polar Lipids) and 2 
mole% phosphatidylethanolamine (Avanti Polar Lipids) in chloroform:methanol (3:1), was 
dried under vacuum to form a lipid film. The surfactant components were combined with 
the crown ether and distilled de-ionized water, and emulsified (Microfluidics Inc) at 20000 
psi for 4 minutes. Particle sizes were measured to be 200±25 nm at 25°C using a laser 
light scattering submicron particle analyzer (Brookhaven Instruments). 
Nanoparticles were administered at a dose of 1 mL/kg body weight in Ketamine 
(87mg/Kg)/Xylazine (13mg/Kg) anesthetized C57/BL6 mice as a bolus through a jugular 
vein catheter. 19F MR signal from the tail was measured on a Varian 4.7T imaging system 
while the mouse was maintained under anesthesia (Ketamine (54mg/Kg/hr)/Xylazine 
(8.2mg/Kg/hr)). Spectra were obtained with a custom-built four-turn solenoid coil via non-
localized 19F spin echo spectroscopy (256 signal averages, TR=1.05s, TE=1ms). In five 
individual trials, the observed decay of in vivo 19F signal intensity was fitted to a bi-
exponential curve (Fig. 1). The obtained exponents were interpreted as half-lives in a two-
compartment model (Fig. 2, Table 1). Median distribution half-life of crown ether 
nanoparticles was 8.23 minutes. Assuming a gamma distribution, distribution half-life 
exhibited a 90% confidence interval of [0.08, 50.67] minutes. Assuming a normal  
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Figure 6.1 19F spectra for one mouse. Depicted spectra reflect an arbitrary scale for signal 
strength. Frequencies are given as PPM assuming a 190 MHz spectrometer frequency. 
The decay in intensity corresponds to points depicted for trial 2 in Fig. 2. 
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Figure 6.2 In vivo 19F signal intensity as a function of time after injection of PFC 
nanoparticles in five mice. Intensity is normalized to the t=50 min value in each trial (the 
t=50 min point was chosen for normalization because it was the earliest data point 
available for all five mice). The table lists distribution and terminal half-life as measured by 
fitting in vivo 19F spectroscopy data to a two-compartment model for each trial.  
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distribution, mean terminal half-life was 181.3±40.7 minutes. Terminal half-life exhibited a 
90% confidence interval of [142.5, 220.0] minutes. 
In Figure 3, normalized in vivo 19F signal intensity for one mouse is plotted alongside 
normalized 19F intensity for blood samples taken from the same mouse.  For three mice, 
19F spectra were obtained from a total of 13 blood samples (4 from one mouse, 4 from 
another, and 5 from a third). Comparing blood intensity data to in vivo intensities predicted 
by fitted bi-exponential curves, we obtained a correlation coefficient (Pearsonian r-value) of 
0.9694 with a 90% confidence interval of [0.92, 0.99]. The average difference between 
normalized blood signal intensity and normalized in vivo signal intensity was 
4.46%±8.06%. Although the trend in fluorine clearance was apparently altered by the 
withdrawal of blood and possibly by infusion of saline, the critical result in these 
experiments was the close correlation between the signal trend in blood samples and the 
trend of in vivo signal. This relationship illustrates the direct and close correspondence 
between in vivo 19F signal intensity and crown ether concentration in the blood. 
Additional experiments were designed to alter the pharmacokinetics of PFC 
nanoparticles administered as above by using doses of “decoy” safflower oil nanoparticles 
that have no fluorine signature16. In three experiments, bolus doses of 3 mL/kg body 
weight, 3 mL/kg body weight, and 4 mL/kg body weight safflower oil particles were injected 
30, 60, and 60 minutes, respectively, prior to injection of 1 mL/kg body weight CE 
nanoparticles. Clearance of the CE particle dose was monitored as described above. 
A representative 19F intensity curve from Figures 1 and 2 is compared to results from 
“decoy” experiments in Figure 4. In all cases, addition of an advance dose of decoy  
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Figure 6.3 In vivo 19F signal intensity and 19F signal intensity in extracted blood as a 
function of time after injection of PFC nanoparticles. For blood data, intensity is normalized 
to the t=26 minutes value (the time of the first blood drawing). For in vivo data, intensity is 
normalized to a t=26 minutes value predicted by a bi-exponential fit to the given data. 
Depicted data is for one mouse. 
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Figure 6.4 In vivo 19F signal intensity as a function of time after injection of PFC 
nanoparticles in four mice. Three of the plots indicate administration of a decoy dose of 
safflower oil particles prior to the dose of PFC nanoparticles (dosing regimens are 
provided in the figure legend). Intensity is normalized to the t=7 min value in each trial. 
Fitted pharmacokinetics parameters are noted in the table. 
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particles extended the clearance time. For the lowest decoy dose and the shortest delay 
prior to CE dosing, the most apparent alteration to clearance kinetics was in the 
distribution half-life. Increasing the delay between doses extended the elimination half-life 
and, with further increase of the decoy dose, the distribution phase of clearance failed to 
manifest. Regarding the two 3 ml/kg decoy doses, we estimate less than a 0.5% likelihood 
of sampling the measured distribution half-lives from the gamma distribution fitted to the 
five non-decoy distribution half-lives. The density of data acquired with 19F NMR allowed 
assessment of the subtle alterations to clearance kinetics observed on application of 
decoy particles. The altered kinetics may not have been apparent in data obtained with 
blood sampling.  
19F MRS, with use of the above methods, was employed to characterize the 
pharmacokinetics of thrombin-inhibiting PFC nanoparticles functionalized with PPACK17. 
The inhibitor was covalently conjugated to the surface of particles including 
diphospholipids carrying carboxy-terminated PEG spacers (1 mole% 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (Avanti Polar 
Lipids) in the lipid film as described above). PPACK particles administered at 1 mL/kg 
body weight manifested a terminal half-life of 105.87±23.38 minutes (n=3). Particles with 
carboxy-terminated PEG spacers, but no conjugated PPACK, exhibited a terminal half-life 
of 240.16±23.42 minutes (n=3). 19F MRS thus allowed characterization of the distinct 
pharmacokinetics of a nanoparticle functionalized for clinically applicable purposes (Fig. 
5). 
Post-mortem 19F images of one mouse receiving a single bolus of PFC particles  
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Figure 6.5 Clearance half-life for different types of nanoparticles. 19F MRS determined 
clearance half-lives for PPACK-functionalized PFC nanoparticles (105.87±23.38 minutes), 
PFC nanoparticles with a surface-conjugated carboxy-PEG spacer (240.16±23.42 
minutes), and non-functionalized PFC nanoparticles (181.3±40.7 minutes). 
 
 
 
 
 
 
 
 
 
 
 
110 
indicated strong accumulation of fluorine signal in the liver and spleen two hours after 
injection of PFC nanoparticles (Fig. 6). The mouse was sacrificed two hours after 
intravenous injection of 1 ml/kg body weight crown ether nanoparticles. 1H (0.5 s TR, 0.02 
s TE, 2 signal averages, 256 by 256 image matrix, 8 cm by 5 cm field of view, 2.2 minute 
acquisition time) and 19F (.8 s TR, .0121 s TE, 64 signal averages, 32 by 32 image matrix, 
8 cm by 5 cm field of view, 2 cm image depth, 27.3 minute acquisition time) spin echo 
images of this mouse were obtained post-mortem with a custom-built open surface coil on 
a Varian 11.7T MR system. 
As anticipated, clearance by the reticuloendothelial system is primarily responsible for 
blood signal diminution18,19. Furthermore, a proportionally small signal was evident in the 
blood (as exhibited by the lack of signal from the aorta). This verifies the assertion based 
on in vivo spectroscopy data fit to the two-compartment model that at two hours t;he 
distributive phase has passed and fluorine has passed from the blood to the liver and 
spleen on its way to clearance. Further imaging data would be necessary to provide 
comprehensive assessment of pharmacodynamics, but the presented image hints at the 
possibility of using imaging in conjunction with the presented spectroscopy method to 
provide a more thorough understanding of the clearance of PFC nanoparticles. 
 
6.3   Discussion 
This work was designed to develop and implement a rapid and accurate non-invasive 
method to sensitively characterize the pharmacokinetics of nanoparticle drug carriers in 
vivo. When obtaining pharmacokinetic data through direct blood or tissue sampling, the 
number of samples often may be limited by the health of the subject, or, in the case of 
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Figure 6.6 19F spin echo coronal projection image (false color) overlaid on a proton spin 
echo coronal slice image (grayscale). The image was taken post-mortem in a mouse 
sacrificed two hours after injection. Accumulation of fluorine in the liver (right) and spleen 
(left) is evident.  
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small animals, by a limited total blood volume1. In contrast, the number of concentration 
measurements permitted by noninvasive characterization of the pharmacokinetics of PFC 
nanoparticles with 19F MRS is limited only by spectra acquisition times. The great 
advantage of PFC nanoparticles for this purpose is the unique spectral signature afforded 
by the 19F nucleus and the large quantity of 19F in each nanoparticle. 
In previous work, the pharmacokinetics of similar nanoparticles have been evaluated 
through chemical analysis of blood samples10,18,19. The circulating half-life of ανβ3-targeted 
nanoparticles in NZW rabbits was determined as ~300 minutes. The shorter circulating 
half-lives reported in this study may be attributable to the open biliary system found in 
mice, but not in rabbits. 
Whether such a technique could be used in humans receiving therapeutic particles is 
conjectural.  However, as is the case with determination of blood oxygenation levels with 
pulse oximeters applied to peripheral digits, it is likely that special coils and acquisition 
strategies can be created to register unique spectral signatures from circulating 
nanoparticles from digits, ear lobes or other propitious sites.  Accordingly, we propose that 
in these cases, the method described here could reduce the need for routine blood 
sampling to define PK parameters and yield individualized clearance kinetics that might be 
useful for medical management as clinical conditions change.  
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Chapter 7 
 
Appendix 2: A Model for Kinetic Characterization of Multivalent Targeted 
Nanoparticles 
 
7.1   Introduction 
 
The biomedical application of nanoparticles often makes use of the capability to 
functionalize nanoparticles with targeting moieties for specific interactions with medically 
relevant macromolecules1,2,3. Nanoparticles specifically directed to biomedical targets have 
been used to provide optical, PET, MRI, and CT contrast4,5,6 in applications including 
tumor metastasis, atherosclerosis, and thrombosis7,8,9,10. The goal behind applying 
nanoparticles in this manner is to derive physiological information from imaging data. For 
instance, a nanoparticle targeted to the αvβ3 integrin in a cancer patient could detect 
angiogenesis in the tumor periphery8. The magnitude of the nanoparticle signal might 
correspond to the risk for tumor metastasis for example.  
Perfluorocarbon nanoparticles targeted to α-thrombin have been proposed and 
demonstrated in the present work. As with αvβ3 targeting of perfluorocarbon nanoparticles, 
the thrombin-targeted particle provides 19F MRI contrast indicative of thrombin activity11,12. 
Particles functionalized with the direct thrombin inhibitors PPACK or bivalirudin can bind to 
active thrombin bound in forming thrombi, allowing both diagnosis and inhibition of a 
prothrombotic surface. While the magnitude of the MRI signal is related to the quantity of 
locally active thrombin that has bound the PPACK NP, a model considering the manner in 
which nanoparticles bind to surface distributions of receptors may provide the best 
translation between imaging data and a true measure of thrombin activity. 
116 
Experimental techniques have been devised for the use of surface plasmon resonance 
to characterize the unique kinetic behaviors of nanoparticles13,14,15. These techniques have 
successfully distinguished the behavior of free ligands from ligands bound on 
nanoparticles, but fail to assign a mechanistic model for the behavior of a multivalent 
ligand. Instead, a two-step Langmuir model has been applied. A model specific to 
multivalent species has not been proposed to interpret the kinetic behavior of 
nanoparticles. 
Here, a model based on analogy to understanding of ligand interactions with cell 
surface receptors16 and Hubble’s model for adhesion of multivalent ligands17 is proposed 
to interpret imaging data reflecting the binding of thrombin-inhibiting nanoparticles to fibrin 
clots. In the context of experimental MRI data sets presented for demonstration, the model 
permits an understanding of the efficacy of two types of nanoparticle as targeting agents 
for clot-bound thrombin. A model for interpretation of time-resolved imaging data 
determined by nanoparticle contrast carries the possibility of general application in using 
imaging data in deriving surface density of specifically targeted receptors in a physiological 
milieu. The model proposed here derives results that rigorously inform the design of a 
thrombin-targeted nanoparticle, yielding a description of the effect of multivalency that 
could optimize the type and quantity of component ligand used on the particle.  
 
7.2   Theory 
Multivalent binding requires special consideration for association and dissociation 
events. A nanoparticle presenting n ligands can only initially attach to its target with one 
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ligand. Furthermore, only particles attached to their targets with only one ligand are able to 
dissociate from a surface. The initial adhesion or dissociation of the nanoparticle is 
described by: 
 
where C1 is the quantity of nanoparticles bound through a single ligand interaction and f is 
the fraction of bound nanoparticles that are attached via only one ligand. RT is the total 
number of receptors, L is the quantity of unbound nanoparticles, and kf and kr are rate 
constants ascribed to the component targeting ligands on the nanoparticles. For purposes 
of this study, the above equation expresses variables in the following units:  
 
Hubble applied the assumption that, after the initial binding event, the association or 
dissociation of each subsequent ligand on a multivalent species obeys identical kinetics17. 
Under equilibrium conditions, this assumption requires that Ka, the ratio of nanoparticles 
bound with k ligands to nanoparticles bound via (k-1) ligands, be the same for all k 
between 2 and n, the total number of ligands carried by the multivalent species. Note that 
in proposing Ka under these conditions, Hubble provides that each of the n ligands on the 
multivalent species must be accessible to the binding surface17. Only a fraction of the 
ligands on a nanoparticle can meet this criterion, and n will refer to this fraction in 
subsequent equations. Based on the assumption that KD is defined by the binding of one 
ligand to one receptor, Hubble derived the fraction of single ligand bound nanoparticles as 
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By analogy to the modeling of dissociation of ligands from cell surface receptors16, a 
rate equation may be established for dissociation of nanoparticles from targets on a 
surface:  
  
where C is the number of nanoparticles bound to the surface, R is the surface density of 
free (unbound) targets on the surface, and L, kf, and kr are as described above. 
 For purposes of this study, the model will analyze the dissociation of nanoparticles 
bound to a surface at a high concentration, with initially near zero concentration in a 
confined surrounding volume. This situation is analogous to the binding and subsequent 
dissociation of vasculature-confined nanoparticles to a thrombus in an occluded artery18. 
The value of L in this situation will correspond to the quantity of dissociated nanoparticles. 
The value of R can be expressed in terms of the total number of targets on the surface RT, 
giving: 
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where C0 is the initial quantity of bound nanoparticles and A is the surface area to which 
the particles are bound. 
 The rate equation can be non-dimensionalized and simplified using: 
  
thus reducing to: 
  
 
Defining  
 
gives a Riccati equation, for which a solution is defined in the literature16 as:  
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where up is the steady state solution, defined according to: 
  
and  
 
 In the analysis of imaging data, A, C, and C0 can be determined experimentally. KD, kr, 
and kf, reflective of the component inhibitor in the multivalent species, can be determined 
via traditional means through analysis of free monovalent inhibitors. Ka requires 
experimental determination through application of the above equation, given a value for 
RT, the surface density of target receptors. 
 
7.3   Methods 
Perfluorocarbon Nanoparticle Preparation 
Nanoparticles were synthesized in accordance with previously described methods19. 
PFC emulsions were formed with 20% (vol/vol) Perfluoro 15-Crown-5 Ether (Exfluor 
Research Corp.) or safflower oil, 2% (wt/vol) of a surfactant mixture, 1.7% (wt/vol) glycerin, 
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and water for the balance. The lipid mixture comprised 99 mole% 
phosphatidylethanolamine (Avanti Polar Lipids) and 1 mole% 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (Avanti Polar Lipids) in 
chloroform:methanol (3:1). The surfactant was dried under vacuum to form a lipid film, 
combined with the water, glycerin, and perfluorocarbon, and emulsified (Microfluidics Inc) 
at 20000 psi for 4 minutes. Particle size was measured with a laser light scattering 
submicron particle analyzer (Brookhaven Instruments). 
Amide formation via carbodiimide was employed to functionalize particles containing 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] 
with bivalirudin or PPACK. After mixing of 1 mL emulsion with 40 mg bivalirudin (Bachem 
California) or 12.5 mg PPACK (Haematologic Technologies) for one hour, EDCI 1-[3-
(Dimethylamino)propyl]-3-ethylcarbodiimide methiodide (2 mg) was added and the mixture 
was incubated overnight to achieve coupling. Excess bivalirudin or PPACK and EDCI were 
removed by overnight dialysis (molecular weight cutoff 3000-5000 g/mol).  
Targeting Nanoparticles to Fibrin Clots 
Targeting of thrombin-inhibiting nanoparticles to human fibrin clots containing known 
quantities of thrombin was used to obtain imaging data for implementation of the above 
multivalent kinetic model. Fibrin clots were formed with human plasma as described 
previously20. Briefly, 281.5 µL citrated human plasma, 16.5 µL of 500 mM CaCl2, and 2 µL 
of 1 U/µL bovine thrombin were mixed and immediately moved to a template for formation 
of a clot around a silk suture. Formed clots were submerged in sterile saline and 
suspended in Eppendorf tubes.  
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 To block nonspecific binding sites, formed clots were exposed to safflower 
nanoemulsion with no functional moiety at 5% by volume (approximately 7 nM particle 
concentration) for two hours at 37ºC on an orbital shaker. After rinsing five times in sterile 
saline, the clots were exposed to bivalirudin (n=3) or PPACK (n=3) nanoparticles under 
identical conditions. At the end of incubation, the clots were again rinsed five times in 
sterile saline. 
Monitoring Dissociation of Nanoparticles from Fibrin Clots 
 Immediately after labeling with thrombin-targeted nanoparticles, clots were analyzed 
with magnetic resonance imaging methods. At various time points, 10 µL of the saline 
surrounding the clot was removed and analyzed via 19F magnetic resonance spectroscopy 
on an 11.7T Varian Imaging system. The supernatant was diluted to 100 µL and placed 
alongside a 0.01 µL perfluorooctyl bromide emulsion diluted to 10 µL inside a custom-built 
single turn solenoid coil. After shimming during continuous proton 90-FID acquisition, a 90-
FID 19F spectrum was acquired with the 2.5s repetition time, 110 ms square pulse width, 
512 signal averages, and 50 kHz spectrum width. 19F spectra containing peaks for 
perfluoro-15-crown-5-ether and the perfluorooctyl bromide standard were employed to 
quantify the content of thrombin-inhibiting perfluoro-15-crown-5-ether emulsion in the 
supernatant samples.  
Following completion of the dissociation time course, clots were subjected to identical 
spectroscopic analysis with a 1 µL perfluorooctyl bromide emulsion standard to determine 
the quantity of particles remaining on each clot. Initial quantity of bound particles was 
inferred through subsequent analysis of samples from each time point. 
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Following acquisition of final spectra, clots were imaged for determination of surface 
area. The clots were imaged in transverse slices with a T2-weighted spin echo multislice 
sequence (2.5 s TR, 150 ms TE, 4 signal averages, 128 phase encoding steps, 128 
frequency encoding steps, 12mmX12mmX16mm field of view, 16 1 mm thick slices). To 
determine surface area, images were processed and analyzed with custom scripts 
developed for Matlab. The outline of the clot was manually delineated in each image slice 
for each clot. 
Data Analysis 
 Values for quantity of bound nanoparticles were non-dimensionalized according to the 
techniques outlined in the theory section. Iterative least squares fitting with Ka as a 
variable parameter allowed characterization of dissociation time courses. 
 
7.4   Simulations and Results 
 In accordance with equation (2), the fraction f of nanoparticles participating in 
association or dissociation events varies with respect to n, the number of ligands on each 
nanoparticle, and Ka, a constant characteristic of the nanoparticle (Fig. 1). Ka is indicative 
of the equilibrium ratio between the number of particles bound by k ligands and the 
number of particles bound by (k-1) ligands, where k is a number between 1 and n. It 
reflects the likelihood of ligand-receptor binding events once the nanoparticle is spatially 
constrained by an initial binding event. The factor f progresses to smaller values with 
increasing Ka. Of note, a more rapid progress to small values of f with increasing Ka is 
observed for larger values of n. The variation of f with n takes the form of a rapidly leveling 
asymptote. In fact, for all n greater than 11, the variation of f with Ka positively correlates  
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Figure 7.1 Variation of the equilibrium fraction f of nanoparticles bound by only one ligand 
with respect to n, the total number of ligands carried by each nanoparticle, and Ka, the 
equilibrium ratio of nanoparticles bound by k ligands and nanoparticles bound by k-1 
ligands, where 2 ≤ k ≤ n. 
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with a variation corresponding to n of 10000 with a Pearsonian value of greater than 
0.9999. Thus, the direct effect of increasing valency n on f (and thus on the effective KD of 
the nanoparticles) is limited for values of n greater than 11. As will be demonstrated, the 
relationship between f, Ka, and n may still be affected by larger values of n. 
 Previous study has characterized antithrombotic perfluorocarbon nanoparticles for 
inhibitor loading and particle size11,12. Based on this work and others, simulations and 
modeling here employed approximate values of 15000 for n, 9 nm for the length of the 
PEG spacer carrying each inhibitor21, and 90 nm for nanoparticle radius11,12. Given these 
parameters and a uniform distribution of targeting ligands on the particle surface, a particle 
in contact with a flat surface would present 1077 ligands capable of contacting the surface. 
For determination of RT, the concentration of thrombin in the clot was assumed to match 
that introduced during clot formation. Accessible depth of thrombin was set at 0.35 mm22, 
yielding a value for η=RT/C0 of approximately 10 for the clots studied here.  
 Simulations employing the above constants with KD and kr values for free PPACK and 
bivalirudin examined the dissociation time courses predicted by equation (5) for various 
values of Ka (Fig. 2, Fig. 3). The low kr value for bivalirudin (as compared to the pseudo-
first order constant for PPACK) assured longer dissociation half lives, assuming identical 
Ka values, for bivalirudin nanoparticles (Fig. 2) as compared to PPACK nanoparticles (Fig. 
3). 
 Using magnetic resonance spectroscopy data, bivalirudin or PPACK nanoparticle 
dissociation after adhesion to clots was measured. The total quantity of nanoparticles on 
each clot was thus determined as a function of time. Fits of equation (5) to this data for  
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Figure 7.2 Variation determined by equation (5) with respect to Ka and time for the relative 
non-dimensionalized number of bivalirudin nanoparticles u bound to a 1 cm2 surface 
presenting thrombin at a concentration reflecting η=10, with KD=121.18 nM, kr=0.010 s-1, 
and n=1077. 
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Figure 7.3 Variation determined by equation (5) with respect to Ka and time for the relative 
non-dimensionalized number of PPACK nanoparticles u bound to a 1 cm2 surface 
presenting thrombin at a concentration reflecting η=10, with KD=4.99 nM, kr=o.030 s-1, and 
n=1077. 
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representative bivalirudin nanoparticle and PPACK nanoparticle clots are depicted in 
Figure 4. For each curve, correlation to data, measured by Pearsonian r-value, was found 
to be greater than 0.9. These fits establsihed values for Ka and f for each dissociation 
curve. For bivalirudin nanoparticles, three clots yielded a Ka value of 1.0047±0.0022, 
corresponding to an f value of 3.89x10-8±3.32x10-8. For PPACK nanoparticles, three clots 
yielded a Ka value of 0.9930±.0001, corresponding to an f value of 4.94x10-5±9.75x10-7. 
 
7.5   Discussion 
 In the experimental portion of this study, the determination of RT, or the number of 
thrombin molecules accessible as receptors, relied on a hypothetical value for nanoparticle 
penetration depth and an informed approximation as to the concentration of thrombin in 
the formed clots.  With a greater degree of precision in determination of RT, an experiment 
design such as that implemented here would allow a more precise determination of Ka. 
Some options would include high-resolution 19F imaging could best indicate the depth of 
perfluorocarbon nanoparticle penetration into clots via surface adsorption. Fluorophore 
incorporation in nanoparticles could permit optical contrast in microscopy of sectioned 
clots, in turn allowing still higher resolution and sensitivity in determination of particle 
depth23. For accurate determination of thrombin concentration, 125I labeling of thrombin has 
previously allowed tracking of thrombin quantity in clots synthesized with methods 
analogous to those in the current work24. The refined Ka value could be applied to studies 
with unknown receptor concentration (such as in an in vivo imaging experiment), 
permitting a fit of a dissociation time course with RT as a varying parameter (Fig. 5). The  
129 
 
Figure 7.4 Data and fitted values from equation (5) for dissociation of bivalirudin (a) or 
PPACK (b) nanoparticles from human fibrin clots. For bivalirudin nanoparticles, the fitted 
curve represents values of Ka = 1.0011 and f = 9.3060x10-8. For PPACK nanoparticles, the 
fitted curve represents values of Ka = 0.9931 and f = 4.7983x10-5. 
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Figure 7.5 Variation determined by equation (5) with respect to η and time for the relative 
non-dimensionalized number of bivalirudin (a) or PPACK (b) nanoparticles u bound to a 1 
cm2 surface presenting thrombin at a concentration reflecting η, with KD=121.18 (a) or 
KD=4.99 nM (b), kr=0.010 s-1 (a) or kr=0.030 s-1 (b), n=1077, and Ka=1.0047 (a) or 
Ka=0.9930 (b).  
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consequence of such a data fit would be a rigorous derivation of the quantity of target 
receptor from time-resolved imaging data.  
The determination of Ka also permits the assessment of the physical properties of 
nanoparticles containing different ligand moieties. Ka itself is indicative of a degree of 
cooperativity between the first ligand-receptor interaction and subsequent interactions for 
the same nanoparticle. This cooperativity can supersede the behavior of individual ligands, 
resulting in values of f that induce an effective nanoparticle KD that contradicts 
assumptions based on the KD of the component ligand. The f of 3.89x10-8 for bivalirudin 
nanoparticles assures a 4.71x10-15 value for fKD (where KD is 121.18 nM). The f of 
4.94x10-5 for PPACK nanoparticles renders an fKD value of 2.46x10-13, greater than that 
observed for bivalirudin nanoparticles, despite an effective KD of 4.99 nM for PPACK itself. 
The lower affinity of bivalirudin for thrombin may be attributable to its larger size and the 
necessity that it forms an interaction with thrombin’s active site and exosite 125. 
Conversely, PPACK is a tripeptide chloromethyl ketone with little secondary structure and 
capacity for interaction only with the thrombin active site26. For the case of a bound 
nanoparticles, bivalirudin is spatially constrained, seemingly achieving interaction with 
thrombin with greater ease. The apparent entropic advantage achieved through spatial 
constraint of PPACK is lesser.  
According to the calculated Ka value, the present model may inform the choice between 
bivalirudin and PPACK as the functional moiety for a thrombin-targeted nanoparticle. 
Hubble’s analysis of multivalent binding17 could further inform the design of thrombin-
targeted nanoparticles through optimization of the quantity of ligands carried by each 
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particle. For the case of large receptor concentration, the standard binding isotherm gives 
a ration between the quantity of multivalent bound and singly bound nanoparticles as:   
 
Given excess receptors as above and L, KD, and f reflective of values employed or 
determined in this study for experiments with bivalirudin and PPACK nanoparticles, it is 
possible to maximize O with respect to the ligand valency n (Figure 6). The maximum 
value of O indicates the ligand loading quantity at which the greatest relative quantity of 
multivalent interactions is expected. For this value of n, the expectation of a singly bound 
state and thus the availability for dissociation is minimized. A maximum is observed for 
bivalirudin at n=33 and for PPACK at n=12.  
 The model presented herein can be applied to experiments detecting either association 
or dissociation of targeted nanoparticles from a surface presenting a specific receptor. The 
nanoparticles represent multivalent ligands for these receptors. Affinity of targeted 
nanoparticles for a target surface is determined by both KD, the dissociation constant for 
the component ligand, and Ka, a factor introduced by Hubble to account for the behavior of 
ligands on a nanoparticle that is already adhered to a surface17. More precisely, the 
dissociation rate for the nanoparticles examined is shown to depend on Ka, KD, and the off 
rate, kr. The unique properties of Ka are shown here to allow a lower affinity inhibitor, 
bivalirudin, to functionalize nanoparticles adhering more tightly to thrombin than those 
functionalized by a higher affinity ligand, PPACK. Given inference of an isotherm specific 
to desired data observation, it is also possible to determine an optimal ligand loading n on  
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Figure 7.6 Assuming a binding isotherm with excess receptor, the relative quantity of 
multivalent-bound bivalirudin (a) or PPACK (b) nanoparticles was determined with respect 
to nanoparticle valency n according to equation (8) with KD=121.18 (a) or KD=4.99 nM (b) 
and f = 9.3060x10-8 (a) or 4.7983x10-5 (b). Optimization was observed at n=33 for 
bivalirudin nanoparticles and n=12 for PPACK nanoparticles.  
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nanoparticles. Finally, and most relevantly, given knowledge of Ka determined through 
experiments such as those demonstrated here, the equations presented here allow 
quantitative assessment of receptor density from dissociation curves measured in imaging 
experiments.  
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